Advertisement

Die Gestagene pp 1125-1178 | Cite as

Die antikonzeptionelle Therapie

  • J. Haller
Part of the Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology book series (HEP, volume 22 / 1)

Zusammenfassung

Die ersten Beobachtungen über eine temporäre Ovulationshemmung durch Hormone gehen bis auf Haberlandt[153] zurück, der schon 1921 zeigen konnte, daß die Transplantation von Ovarien schwangerer Versuchstiere auf geschlechtsreife Tiere gleicher Species zu einer zeitlich begrenzten Sterilität der Tiere mit den transplantierten Eierstöcken führt. Diese Wirkung wurde dem hohen Gehalt der transplantierten Ovarien an Corpus luteum-Hormon zugeschrieben.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Adlercreutz, H.: Cholestatic jaundice caused by contraceptive steroids and its relation to intrahepatic cholestatic jaundice of pregnancy. In: C. Cassano (ed.), Research on steroids, vol. II, p. 521. Rom: Il pensiero Scientifico 1966.Google Scholar
  2. [2]
    Amreich, J.: Antikonzipientia und die durch sie verursachten Schädigungen. Wien. med. Wsehr. 112,9 (1962).Google Scholar
  3. [3]
    Anderton, E.: Clinical trials of oral progestogens. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,389 (1964).Google Scholar
  4. [4]
    Andolsek, L.: Influence of estrogen-progestin combinations on menstrual cycle. In: C. Cassano (ed.), Research on steroids, vol. II, p. 447. Rom: II Pensiero Scientifico 1966.Google Scholar
  5. [5]
    Andreoli, C.: Human endometrial picture after sequential and combination regimen. In: C. Cassano (ed.), Research on steroids, vol. II, p. 469. Rom: II Pensiero Scientifico 1966.Google Scholar
  6. [6]
    Andreoli, C., E. Morano, and P. Yischi: Endometrial morphology under the optical and electron microscope after prolonged treatment with some estroprogestational combinations. Excerpta med. (Amst.), Int. Congr. Ser. III, 352 (1966).Google Scholar
  7. [7]
    Andrews, W. C., and M. C. Andrews : The use of progestins for oral contraception. Sth. med. J. (Bgham, Ala.) 55,454 (1962).CrossRefGoogle Scholar
  8. [8]
    Andrews, W. C., and M. C. Andrews Reduction of side effects from ovulation suppression by the use of newer progestin combinations. 19th Ann. Meeting Amer. Soc. Study Steril., p. 75. New York 1963.Google Scholar
  9. [9]
    Andrews, W. C., and M. C. Andrews Patient acceptance of oral contraceptives. Metabolism 14,446 (1965).PubMedCrossRefGoogle Scholar
  10. [10]
    Apostolakis, M.: The effects of HCG and ACTH on the urinary excretion of testosterone and epitestosterone in male patients with various endocrine disorders. Proceed. The Pord Foundation Int. Conf. on the physiology of human reproduction, Venice, p. 17 (1966).Google Scholar
  11. [11]
    Arnold, M., St. Cloeren, M. Mall, E. More, R. H. H.Richter, Fr. Roth, H. Stamm u. H. Wyss: Vorläufige Resultate vergleichender Versuche mit oralen Kontrazeptiva, 2. Teil. Verhandl. Jahresversammlung der Schweiz. Gesellschaft f. Gynäk., Juni 1966,Lugano.Google Scholar
  12. [12]
    Ayre, J. E.: Influence of Enovid upon carcinoma in situ and precancerous cervical lesions. Proc. IVth World Congr. Int. Ped. Gynec. Obstet. 1964.Google Scholar
  13. [13]
    Baines, G. F.: Jaundice in a patient taking norethisterone compound tablets. Lancet 19651,No 7376,108.CrossRefGoogle Scholar
  14. [14]
    Bakker, C. B., and C. R. Dightman: Psychological factors in fertility control. Fertil. and Steril. 15,559 (1964).Google Scholar
  15. [15]
    Bayot, Dr.: Study of liver function during hormonal antiovulatory treatment. In: C. Cassano (ed.), Research on steroids, vol. II, p. 513. Rom: II Pensiero Scientifica 1966.Google Scholar
  16. [16]
    Becker, F. T.: Porphyria cutanea tarda induced by estrogens. Arch. derm. 92,252 (1965).CrossRefGoogle Scholar
  17. [17]
    Becker, W.: Unerbetene Bander. Med. Klin. 59,1402 (1964).PubMedGoogle Scholar
  18. [18]
    Behrmann, S. J.: Comparative findings in control of ovulation with various steroids. Excerpta med. (Amst.) Int. Congr. ser. 111,198 (1966).Google Scholar
  19. [19]
    Bell, E. T., A. L.Herbst, M. Krishnamurti, and J. A. Loraine: Urinary gonadotrophs excretion during and following long-term therapy by oral progestogens. Excerpta med. (Amst.) Int. Congr. Ser. 111,197 (1966).Google Scholar
  20. [20]
    Berkoth, E.: Zur Zyklusanalyse aus dem Zervikalsekret. Z. Geburtsh. Gynäk. 147,76 (1956).Google Scholar
  21. [21]
    Besch, P. K., R. D.Barry, N. Vorys, V. Stevens, and J. C. Ullery: A review of some aspects of the metabolism of progestational agents. Metabolism 14,432 (1965).PubMedCrossRefGoogle Scholar
  22. [22]
    Besch, P. K., N. Vorys, J. C.Ullery, V. Stevens, and R. D. Barry: Some systemic effects of a progestational agent. Metabolism 14,387 (1965).PubMedCrossRefGoogle Scholar
  23. [23]
    Bialy, G., and G. Pincus : The pharmacology of progesterone. Med. Ann. D.C. 81,136 (1962).Google Scholar
  24. [24]
    Bickenbach, W., u. E. Paulikovics: Hemmung der Follikelreifung durch Progesteron bei der Frau. Zbl. Gynäk. 68,153 (1944).Google Scholar
  25. [25]
    Binks, R., P. Cambourn, and R. A. Pap worth: Preliminary report of a clinical trial of oral norethynodrel for fertility control. Med. J. Aust. 1962 I, 716.Google Scholar
  26. [26]
    Board, J. A., and D. S. Borland: Sequential oral contraception using DMAP. Fertil. and Steril. 17,234 (1966).Google Scholar
  27. [27]
    Bockner, V.: The contraceptive pill: A clinical evaluation of its long-term use. Med. J. Aust. 1963 I, 809.Google Scholar
  28. [28]
    Böhnel, J., u. A. Stacher: Erhöhte Thrombosebereitschaft durch Ovulationshemmer? Med. Klin. 60,1951 (1965).PubMedGoogle Scholar
  29. [29]
    Borglin, N.: Inhibitory effect of Lynestrenol and Lyndiol on human ovarian function. Int. J. Fertil. 9,17 (1964).PubMedGoogle Scholar
  30. [30]
    Borglin, N. E.: Oral contraceptives and liver damage. Brit. med. J. 19651,1289.Google Scholar
  31. [31]
    Borushek, S., M. R. Abell L.Smith, and J. J. Gold: Effects of Provest on the endometrium. Int. J. Fertil. 8,605 (1963).PubMedGoogle Scholar
  32. [32]
    Bottermann, P., K. Kopetz, P. Dieterle, P. C.Scriba, W. Hochheuser, K. Schleypen, K. Horn, M. Dambacher u. K. Schwarz: Klinische Untersuchungen über die Glukosetoleranz sowie Bestimmungen von Insulin, Trijodthyronin-Bindung und der 11-Hydroxycorticosteroide im Serum unter einer Gestagen-Oestrogen-Therapie. Kongreßbericht 12. Symposion der Deutschen Gesellschaft für Endokrinologie Wiesbaden, 1966.Google Scholar
  33. [33]
    Bowman, R.: Some clinical experience in the oral control of conception. Med. J. Aust. 19621,715.Google Scholar
  34. [34]
    Braitenberg, H., u. L. Veltkay: Zur therapeutischen Verwendbarkeit der hormonellen Ovulationsblockade. Wien. med. Wschr. 113,716 (1963).PubMedGoogle Scholar
  35. [35]
    Brehm, H.: Circulation, blood coagulation and clinical observations during hormonal suppression. Int. J. Fertil. 9,45 (1964).PubMedGoogle Scholar
  36. [36]
    Brehm, H., Über moderne Konzeptionsverhütung. Praxis 54,1154 (1965).PubMedGoogle Scholar
  37. [37]
    Breuer, H.: Studies on the metabolism of 17a-ethinyl-19-nortestosterone. Int. J. Fertil. 9,181 (1964).PubMedGoogle Scholar
  38. [38]
    Brown, J. B., and H. A. F. Blair: Urinary oestrogen metabolites of 19-norethisterone and its esters. Proc. roy. Soc. Med. 58,433 (1960).Google Scholar
  39. [39]
    Brown, J. B., K. Fotherby, and J. A. Loraine: The effect of 17a-ethinyl-19-nortesterone (norethisterone) on the urinary excretion of oestrogens, pregnandiol and gonadotrophins during the menstrual cycle. Proc. roy. Soc. Med. 58,341 (1960).Google Scholar
  40. [40]
    Buchholz, R.: Untersuchungen über die Beeinflussung der Gonadotropinausscheidung beim Menschen durch Keimdrüsenhormone. Geburtsh. u. Frauenheilk. 19,851 (1959).Google Scholar
  41. [41]
    Buchholz, R., L. Nocke u. W. Nocke: Untersuchungen über den Wirkungsmechanismus von Äthinylnortestosteron bei der Unterdrückung der Ovulation. Geburtsh. u. Frauenheilk. 22,923 (1962).Google Scholar
  42. [42]
    Buchholz, R., L. Nocke u. W. Nocke The influence of gestagens on the urinary excretion of pituitary gonadotropins, estrogens and pregnanediol in women in the postmenopause and during the menstrual cycle. Int. J. Fertil. 9,231 (1964).PubMedGoogle Scholar
  43. [43]
    Buchler, D., and J.C. Warren: Effects of estrogen on glucose tolerance. Amer. J. Obstet. Gynec. 95,479 (1966).PubMedGoogle Scholar
  44. [44]
    Büngeler, W., u. W. Dontenwill: Fragekastenantwort (Hormone und Krebs). Münch. med. Wschr. 102,985 (1960).Google Scholar
  45. [45]
    Büngeler, W., u. W. Dontenwill Hormonell ausgelöste geschwulstartige Hyperplasien, hyperplasiogene Ge schwülste und ihre Verhaltensweisen. Dtsch. med. Wschr. 84,1885 (1959).CrossRefGoogle Scholar
  46. [46]
    Butler, J. K. : A review of mortality statistics relating to thromboembolic disease in oral contraceptive users and in non-users. In: O. Cassano (ed.), Research on steroids, vol. II, p. 509. Rom: II Pensiero Scientifico 1966.Google Scholar
  47. [47]
    Carlström, H., S. Höglund, and P. Reizenstein: Oral contraceptives and liver damage, correspondence. Brit. med. J. 1965 I, No 5440,993.CrossRefGoogle Scholar
  48. [48]
    Chang, M. C., and R. Yanagimachi: Effect of estrogens and other compounds as oral antifertility agents on the development of rabbit ova and hamster embryos. Fertil. and Steril. 16,281 (1965).Google Scholar
  49. [49]
    Charles, D.: Iatrogenic endometrial pattern. In: C. Cassano (ed.), Research on steroids, vol. II, p. 477. Rom: H Pensiero Scientifico 1966.Google Scholar
  50. [50]
    Cherniok, B. A.: Side effects of cyclic therapy with norethindrone and mestranol. Fertil. and Steril. 16,445 (1965).Google Scholar
  51. [51]
    Chinnatamby, S.: I. Clinical trial of oral contraceptives Enovid and Conovid. II. Effect of oral contraceptive (Conovid E) on lactation. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,319 (1964).Google Scholar
  52. [52]
    Chinnatamby, S., Inhibition of ovulation. Excerpta med. (Amst.), Int. Congr. Ser. 111,196 (1966).Google Scholar
  53. [53]
    Chung Ching San: Clinical trials on oral contraceptives in Singapore Family Planning Association. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,382 (1964).Google Scholar
  54. [54]
    Clauberg, C.: Ovarium, Hypophyse und Schwangerschaft in ihrer Beziehung zur Frauenheilkunde. In: Handbuch der Gynäkologie, hrsg. von Yeith u. J. W. Stöckel, 3. Aufl., 9. Bd., S. 368. München: J. F. Bergmann 1936.Google Scholar
  55. [55]
    Clyman, M. C.: Electron-microscopic changes produced in the human endometrium by norethindrone acetate with ethinyl estradiol. Fertil. and Steril. 14,352 (1963).Google Scholar
  56. [56]
    Cobb, J. C., S. Farhat, N. A.Shah, S. J. Ameen, and P. Harper: Oral contraceptive program synchronized with moon phase. Fertil. and Steril. 17,559 (1966).Google Scholar
  57. [57]
    Cohen, M. R., and M. Perez-Pelaez: The effect of norethindrone acetate-ethinyl estradiol clomiphene citrate and Dydrogesterone on Spinnbarkeit. Fertil. and Steril. 16,141 (1965).Google Scholar
  58. [58]
    Cook, H.H., C. J. Gamble, and A. P. Satterthwaite: Oral contraception by norethinodrel. Amer. J. Obstet. Gynec. 82,437 (1961).PubMedGoogle Scholar
  59. [59]
    Copeman, P. W. M., D. J. Cripps, and R. Summerly: Cutaneous hepatic prophyria and oestrogens. Brit. med. J. 1966 I, 461.CrossRefGoogle Scholar
  60. [60]
    Coutinho, E. M., J. C. De Souzy, and A. I. Csapo: Reversible sterility induced by medroxyprogesterone injections. Fertil. and Steril. 17,261 (1966).Google Scholar
  61. [61]
    Council on Drugs: New drags and developments in therapeutics Norethinodrel with mestranol (envoid). J. Amer. med. Ass. 183,949 (1963).CrossRefGoogle Scholar
  62. [62]
    Cross, J. W.: New synthetic steroid progestins. Fertil. and Steril. 10,361 (1959).Google Scholar
  63. [63]
    Cullberg, G., R. Lundström, and U. Stenram: Brit. med. J. 1965 I, No 5436,695.CrossRefGoogle Scholar
  64. [64]
    Dacic, Z.: Serum-Enzymuntersuehungen zur Frage der Leberschädigung durch orale Ovulationshemmer. Med. Welt 2,108 (1966).PubMedGoogle Scholar
  65. [65]
    Datta, H., R. Nath, and R. R. Chaudhury: Oral contraceptives and liver damage. Brit. med. J. 1965 II, 476.CrossRefGoogle Scholar
  66. [66]
    Dean, G.: Oral contraceptives in porphyria variegata. S.Afr. med. J. 89,279 (1965).Google Scholar
  67. [67]
    Demol, R., and J. Ferin: The urinary gonadotropin content during treatment with Lynestrenol. Int. J. Fertil. 9,197 (1964).Google Scholar
  68. [68]
    Desaulles, P. A., u. C. Krähenbühl: Moderne Entwicklung auf dem Gebiet der Gestagentherapie. 6. Sympos. dtsch. Ges. Endokr. 1959,S. 1. Berlin-Göttingen- Heidelberg: Springer 1960.Google Scholar
  69. [69]
    Desaulles, P. A., u. C. Krähenbühl Comparaison du spectre d’activité de certains gestagènes de synthèse. Acta endocr. (Kbh.) 40,217 (1962).Google Scholar
  70. [70]
    Diczfalusy, E.: Probable mode of action of oral contraceptives. Brit. med. J. 1965 II, 1394.CrossRefGoogle Scholar
  71. [71]
    Diczfalusy, E. Probable mode of action of oral contraceptives. In: C. Cassano (ed.), Research on steroids, vol. II, p. 389. Rom : II Pensiero Scientifico 1966.Google Scholar
  72. [72]
    Diczfalusy, E., E. Johannisson, K.-G. Tillinger, and G. Bettendore : Studies on the effect of testosterone on the ovarian response to exogenous human hypophysial gonadotrophs (HHG) in amenorrhoeie women. J. Int. Fed. Gynaec. Obstet. 1,145 (1963).Google Scholar
  73. [73]
    Diddle, A. W., G. F.Watts, W. H. Gardner, and P. J. Williamson: Oral contraceptive medication: A prolonged experience. Amer. J. Obstet. Gynec. 95,489 (1966).PubMedGoogle Scholar
  74. [74]
    Dietel, H.: Konzeptionsverhütung. Hamburger Ärztebl. 16,112 (1962).Google Scholar
  75. [75]
    Dingle, J. T.: Preliminary report on Provest study. Int. J. Fertil. 8,711 (1963).PubMedGoogle Scholar
  76. [76]
    Dockerty, M. B., R.A. Smith, and R. E. Symmonds: Pseudomalignant endometrial changes induced by administration of new synthetic progestins. Proc. Mayo Clin. 34,321 (1959).Google Scholar
  77. [77]
    Dodek, O. I., E. J. Segre, and E. L. Klaiber: Effects of enovid on Cortisol metabolism. Amer. J. Obstet. Gynee. 93,173 (1965).Google Scholar
  78. [78]
    Doering, P., u. E. Schmele: Ergebnisse des J131-Trijodthyromntestes mit einem Ionenaustauscherharz. Strahlenforsch, u. Strahlenbeh. 4,272 (1963).Google Scholar
  79. [79]
    Doran, T. A., J. L.Harkins, A. G. Gornall, and D. W. Thompson: Clinical and laboratory assessment of a new progestational agent. Canad. med. Ass. J. 91,900 (1964).PubMedGoogle Scholar
  80. [80]
    Döring, G. K.: Kann der Wechsel zwischen verschiedenen Ovulationshemmern nach teilige Folgen haben ? Dtsch. med. Wschr. 17,785 (1965).Google Scholar
  81. [81]
    Döring, G. K. Darf eine stillende Mutter Ovulationshemmer einnehmen oder sind Schädigungen beim Säugling zu befürchten? Dtsch. med. Wschr. 90,2176 (1965).CrossRefGoogle Scholar
  82. [82]
    Döring, G. K. Empfängnisverhütung. Stuttgart: Georg Thieme 1966.Google Scholar
  83. [83]
    Döring, G. K. Sind nach längerer kontrazeptiver Therapie mit Ovulationshemmern eine erhöhte Konzeptionschance und eine Häufung von Mehrlingsgeburten zu beobachten? Dtsch. med. Wschr. 91,1134 (1966).Google Scholar
  84. [84]
    Döring, G. K., L. Akhundzaden u. B. Herzing: Über den Bremseffekt von Methyl-Nortestosteron auf die Ovarialfunktion weißer Ratten. Arch. Gynäk. 192,129 (1959).CrossRefGoogle Scholar
  85. [85]
    Dohrmann, R. E., u. G. Giffels: Das Verhalten der Glutamat-Pyruvat-Transaminase, Aldose, ß- Glukuronidase und des Eiweißspektrums im Serum unter der Einwirkung eines Ovulationshemmers. Med. Klin. 60,1844 (1965).PubMedGoogle Scholar
  86. [86]
    Dominguez, H., F. Simowitz, and R. B. Greenblatt: Clinical evaluation of a new oral progestinchlormadinone. Amer. J. Obstet. Gynec. 84,1478 (1962).PubMedGoogle Scholar
  87. [87]
    Donayre, J., and G. Pinous: Effects of enovid on blood clotting factors. Metabolism 14,411 (1965).CrossRefGoogle Scholar
  88. [88]
    Dontenwill, W. : Bedeutung der Hormone für die Geschwulstentstehung. Zbl. Gynäk. 83,1704 (1961).Google Scholar
  89. [89]
    Dontenwill, W. Kolposkopische, zoologische und histologische Portiobefunde unter ovulationshemmender Medikation. Münch, med. Wschr. 107,491 (1965).Google Scholar
  90. [90]
    Drill, V. A.: Steroids inhibiting ovulation. Jap. J. Pharmacol. 11,88 (1962).PubMedCrossRefGoogle Scholar
  91. [91]
    Drill, V. A. Contraceptive effect of oral progestins. Properties of SC 11800,a new oral ovula tion inhibitor. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,427 (1964).Google Scholar
  92. [92]
    Drill, V. A. Endocrine properties and long-term safety of oral contraceptives. Metabolism 14,295 (1965).PubMedCrossRefGoogle Scholar
  93. [93]
    Dijkes, M. N. G., H. Kopera, and G. L. Ijzermann: Clinical experience with cyclical administration of lynestrenol in combination with an estrogen for fertility control. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,336 (1964).Google Scholar
  94. [94]
    Eckstein, P., J. A. H.Waterhouse, G. M.Bond, W. G.Mills, D. M. Sandilands, and D. M. Shotton: The Birmingham oral contraceptive trial. Brit. med. J. 1961 II, 1172.CrossRefGoogle Scholar
  95. [95]
    Egeberg, O., and P. A. Owren: Oral contraception and blood coagulability. Brit. med. J. 1968 I, 220.Google Scholar
  96. [96]
    Eger, W.: The necrotropic liver-protective substances. In: The liver, vol. II, p. 553. New York: Academic Press 1964.Google Scholar
  97. [97]
    Eichner, E.: The clinical uses of Provest. Int. J. Fertil. 8,673 (1963).PubMedGoogle Scholar
  98. [98]
    Eichner, E. Medroxyprogesterone acetate. Its use in family spacing. Ohio St. med. J. 59,684 (1963).Google Scholar
  99. [99]
    Eisalo, A., P. A. Järvinen, and T. Luukkatnen: Hepatic impairment during the intake of contraceptive pills: Clinical trial with postmenopausal women. Brit. med. J. 1964 II, 426.CrossRefGoogle Scholar
  100. [100]
    Eisalo, A., P. A. Järvinen, and T. Luukkatnen, Liver-function tests during intake of contraceptive tablets in pre-menopausal women. Brit. med. J. 1965 I, No 5447,1416.CrossRefGoogle Scholar
  101. [101]
    Ellington, E. F., A. N. Contopoulos, and M. T. Clegg: The influence of progesterone on pituitary gonadotrophic secretion. Proc. 7th Conf. Int. Planned Parenthood Fed. Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,487 (1964).Google Scholar
  102. [102]
    Elliott, J., and J. Hendry: Cholestatic jaundice complicating pregnancy: recurrence after norethynodrel with ethynylestradiol (Enovid). Canad. med. Ass. J. 92,344 (1965).PubMedGoogle Scholar
  103. [103]
    Epstein, J. A., H. S. Kuppermann, and A. Cutler: Comparative pharmacological and clinical activity of 19-Nortestosterone and 17-hydroxy-progesterone derivatives in man. Ann. N.Y. Acad. Sci. 71,560 (1958).PubMedCrossRefGoogle Scholar
  104. Erb, H., u. H.Keller: Klinische und experimentelle Erfahrungen mit hormonalen Ovulationshemmern. Gynaecologia (Basel) 158,1 (1964).Google Scholar
  105. [105]
    Erb, H., u. K.S.Ludwig: Corpus-luteum-Bildung während Einnahme eines hormonalen Antikonzeptivums. Gynaecologia (Basel) 159,309 (1965).Google Scholar
  106. [106]
    Ercoli, A.: Personal Research within the framework of a short history of the fertilityantifertility steroids. In: C. Cassano (ed.), Research on steroids, vol. II, p. 393. Rom: II Pensiero Scientifico 1966.Google Scholar
  107. [107]
    Esoda, E. C. J.: Chloasma from progestational oral contraceptives. Arch. Derm. 87,486 (1963).CrossRefGoogle Scholar
  108. [108]
    Falconi, G.: A proposed new procedure for the evaluation of antiovulatory drugs in the rat. In: C. Cassano (ed.), Research on steroids, vol. II, p. 375. Rom: II Pensiero Scientifico 1966.Google Scholar
  109. [109]
    Faust, J. M., and E. T. Tyler: Ophthalmologic findings in patients using oral contra ception. Fertil. and Steril. 17,1 (1966).Google Scholar
  110. [110]
    FDA (Food and Drug Administration; USA): Report on Enovid. J. Amer. med. Ass. 185,774 (1963).Google Scholar
  111. [111]
    FDA Statement on oral contraceptives. F-D-C-Reports, August 15th, 1966.Google Scholar
  112. [112]
    Felton, H. T., E. W. Hoelscher, and D.P.Schwartz: Evaluation of use of an injectable progestinestrogen for contraception. Fertil. and Steril. 16,665 (1965).Google Scholar
  113. [113]
    Ferin, J., J. Charles, G. Rommelart, and A. Beuseelinck: Ovarian inhibition during lactation. Int. J. Fertil. 9,41 (1964).PubMedGoogle Scholar
  114. [114]
    Finkelstein, M., D. Serr, and J. Weideneeld : Evaluation of ovarian function in; women by the estimation of urinary pregnanetriol during treatment with 19-norsteroids. I: C. Cassano (ed.), Research on steroids, vol. II, p. 399. Rom: II Pensiero Scientifico 1966.Google Scholar
  115. [115]
    Firat, D., and L. Stutzman: Blood thrombocyte levels after administration of equine estrogens. Proc. Soc. exp. Biol. (N.Y.) 103,474 (1960).Google Scholar
  116. [116]
    Flowers jr. C. E.: New developments in ovulation control. In: E. Goldfarb, Advances in the tratment of menstrual dysfunction, p. 141. Philadelphia: Lea & Febiger 1964.Google Scholar
  117. [117]
    Fotherby, K., S. Kamyab, and P. Littleton: Metabolism of synthetic progestational compounds. J. Endocr. 8,33 (1965).Google Scholar
  118. [118]
    Fotherby, K., P. Littleton, S. Kamyab, and A. Klopper: Metabolism of synthetic progestational compounds in humans. Excerpta med. (Amst.), Int. Congr. Ser. 111,198 (1966).Google Scholar
  119. [119]
    Frank, R.: Use of oral compounds. Proc. 7th Conf. Int. Planned Parenthood Fed. Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,323 (1964).Google Scholar
  120. [120]
    Frank, R., and Chr. Tietze: Acceptance of an oral contraceptive program in a large metro politan area. Amer. J. Obstet. Gynec. 98,122 (1965).Google Scholar
  121. [121]
    Frerichs, H., S. Grote, E. Severidt u. W. Creutzfeldt: Änderungen der Glukose assimilation im Verlauf des Menstruationszyklus und während der Behandlung mit einem Ovulationshemmer (Äthinylnortestosteronacetat, Anovlar). Verh. 12. Symposion der Deutschen Gesellschaft für Endokrinologie und 2. Tag. Dtsch. Diabetes- Gesellschaft, Wiesbaden. Berlin-Göttingen-Heidelberg: Springer 1966.Google Scholar
  122. [122]
    Frick, H. C.: Progestational drugs in the management of endometrial cancer. Meta bolism 14,348 (1965).CrossRefGoogle Scholar
  123. [123]
    Fuchs, F., S. Johnsen, and K. Alling Moeller: Studies on pituitary, adrenocortical and ovarian function during treatment with medroxyprogesterone acetate. Int. J. Fertil. 9,147 (1964).PubMedGoogle Scholar
  124. [124]
    Garcia, C. R., and G. Pincus : Clinical consideration of oral hormonal control of human fertility. Clin. Obstet. Gynec. 7,844 (1964).CrossRefGoogle Scholar
  125. [125]
    Garcia, C. R., and G. Pincus, Ovulation inhibition by progestin-estrogen combination. Int. J. Fertil. 9,95(1964)Google Scholar
  126. [126]
    Garcia, C. R., and G. Pincus, and J. Rock: Effects of three 19-norsteroids on human ovulation and menstrua tion. Amer. J. Obstet. Gynec. 75,82 (1958).PubMedGoogle Scholar
  127. [127]
    Garcia, C. R., J. Rock, and G. Pincus : Observations on prolonged administration of Enovid. In: Proe. of a Sympos. on Enovid, Chicago, 25th November, 1958.Google Scholar
  128. [128]
    Gershberg, H., Z. Javier, and M. Hülse: Glucose tolerance in women receiving an ovulatory suppressant. Diabetes 18,378 (1964).Google Scholar
  129. [129]
    Geschickter, Ch. F., and C. G. Hajrtmann: Mammary response to prolonged estrogenic stimulation in the monkey. Cancer (Philad.) 12,767 (1959).CrossRefGoogle Scholar
  130. [130]
    Gesenius, H.: Orale Empfängnisverhütung. Med. Klin. 58,897 (1963).PubMedGoogle Scholar
  131. [131]
    Gold, J. J., A. Scommegna, and S. Borushek: The clinical use of ovulation sup pressants. Med. Clin. N.Amer. 47,131 (1963).PubMedGoogle Scholar
  132. [132]
    Gold, J. J., L. Smith, A. Scommegna, and S. Borushek: The efficacy of Provest in inhibiting ovulation. Int. J. Fertil. 8,725 (1963).PubMedGoogle Scholar
  133. [133]
    Goldfarb, A. F.: Clinical experience with Provest. Int. J. Fertil. 8,635 (1963).PubMedGoogle Scholar
  134. [134]
    Goldfarb, A. F. Uterine utilisation of steroids. Its role in oral contraception. Metabolism 14,339(1965).Google Scholar
  135. [135]
    Goldzieher, J. W.: The use of newer progestins as oral contraceptives and in uterine carcinoma. New Phycn. 27,265 (1962).Google Scholar
  136. [136]
    Goldzieheb, J. W.: Newer drugs in oral contraception. Med. Clin. N. Amer. 48,529 (1964).Google Scholar
  137. [137]
    Goldzieher, J. W., C. Becebba, C. Gual, N. B. Livingston jr., M. Maqtjeo, L. E. Moses, and C. Tietze: New oral contraceptive. Sequential estrogen and progestin. Amer. J. Obstet. Gynec. 90,404 (1964).PubMedGoogle Scholar
  138. [138]
    Goldzieher, J. W. N. B. Livingston jr., J. Martinez Manatjtou, and L. E. Moses : The use of sequential estrogen and progestin to inhibit fertility. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,325 (1964).Google Scholar
  139. [139]
    Goldzieher, J. W. J. Mabtinez-Manautou, N. B. Livingston jr., L. E. Moses, and E. Rice-Wbay: The use of sequential estrogen and progestin to inhibit fertility. West. J. Surg. 71,187 (1963).PubMedGoogle Scholar
  140. [140]
    Goldzieher, J. W. J. Mabtinez-Manautou, N. B. Livingston jr., L. E. Moses, and E. Rice-Wbay, Die Zweiphasenbehandlung mit einer ovulationshemmenden östrogen- Gestagen-Kombination. Fortsehr. Med. 82,739 (1964).Google Scholar
  141. [141]
    Goldzieher, J. W., L. E. Moses, and U. L. T. Ellis: Study of norethindrone on contraception. J. Amer. med. Ass. 180,359 (1962).CrossRefGoogle Scholar
  142. [142]
    Goldzieher, J. W., and E. R. Rice-Wbay: Oral contraception. Ch. C. Thomas 1966.Google Scholar
  143. [143]
    M. Schulz-Contbebas, and A. Aranda-Rosell : Fertility following termination of contraception with norethindrone. Amer. J. Obstet. Gynec. 84,1474 (1962).Google Scholar
  144. [144]
    Gould, J.: Control of ovulation with Provest. Int. J. Fertil. 8,737 (1963).PubMedGoogle Scholar
  145. [145]
    Gbaffi, A., u. H. Gummel: Zur Frage der eancerogenen Wirkung der Steroiden Gesehlechtshormone. Dtsch. Gesundh.-Wes. 7,1250 (1952).Google Scholar
  146. [146]
    Gbeenblatt, R. B.: Antiovulatory drugs and indications for their use. Med. Clin. N.Amer. 45,973 (1961).Google Scholar
  147. [147]
    Gboff, D. N.: Suggestion for control of epilepsy. N.Y. St. J. Med. 62,3017 (1962).Google Scholar
  148. [148]
    Gbumbach, M. M., J. R. Duchabme, and R. E. Moloshok: On the fetal masculinizing action of certain oral progestins. J. clin. Endoer. 19,1369 (1959).CrossRefGoogle Scholar
  149. [149]
    Guhb, O.: Kolpokopische, zytologisehe und histologische Portiobefunde unter ovulationshemmender Medikation. Münch, med. Wschr. 107,485 (1965).Google Scholar
  150. [150]
    Guhb, O., Kolposkopische, eytologisehe und histologische Portiobefunde bei ovulations hemmenden Medikamenten. Arch. Gynäk. 202,205 (1965).CrossRefGoogle Scholar
  151. [151]
    Guhb, G.: Beitrag über die Wirkung von Ovulationshemmern auf das Plattenepithel der Portio uteri. Zbl. Gynäk. 25,815 (1966).Google Scholar
  152. [152]
    Guttmacheb, A. F.: Oral contraception. Postgrad. Med. 82,552 (1962).Google Scholar
  153. [153]
    Habeblandt, L.: Über hormonale Sterüisierung des weiblichen Tierkörpers. Münch. med. Wschr. 68. 1577 (1921).Google Scholar
  154. [154]
    Haefeli, H., St. Cloeben u. M. Mall: Ovulationshemmer und Emboliegefahr. Gynaecologia (Basel) 160,281 (1965).Google Scholar
  155. [155]
    de Haen, P.: Sequential medication for birth control. Med. Sei. 13,319 (1963).Google Scholar
  156. [156]
    Halbebstadt, E.: Gerinnungsveränderungen unter oralen Antieonzipientien. Beitr. zur Fertil. u. Steril., S. 102. Stuttgart: Ferdinand Enke 1964.Google Scholar
  157. [157]
    Hall, R. E.: Enovid and thrombophlebitis. Bull. Sloane Hosp. Worn. N.Y. 9,17 (1963).Google Scholar
  158. [158]
    Halleb, J.: Über die Einwirkung von 17a-Äthinyl-19-Nortestosteronönanthat auf Hypophysenzwisehenhirnsystem und Uteruswachstum virgineller Meerschweinchen. Acta endocr. (Kbh.) 35,Suppl. 51,456 (1960).Google Scholar
  159. [159]
    Halleb, J. Empfängnisverhütung durch synthetische Hormone. Landarzt 36,77 (1960).Google Scholar
  160. [160]
    Halleb, J. Der Wirkungsmechanismus der Nor-Gestagene. Klin. Wschr. 38,619 (1960).Google Scholar
  161. [161]
    Halleb, J. Vergleichende Prüfung der Wirkung neuer synthetischer Gestagene auf Hypophyse und Genitalorgane im „Milzovar-Planimetertest“. Verh. III. Weltkongr. Gynäk. Geburtsh., Bd. I, S. 75. Wien: Verlag d. Wien. med. Akad. ärztl. Fortb. 1961.Google Scholar
  162. [162]
    Halleb, J. Beeinflussung der Ovulation durch Gestagene. Geburth. u. Frauenheilk. 22,211 (1962).Google Scholar
  163. [163]
    Halleb, J. Reversibility of norethisterone-acetate induced inhibition of gonadotropic function in the “splenic ovarian graft planimetrie test”. Abstr. I. Int. Congr. Hormonal Steroids, Milano 1962. Excerpta med. (Amst.), Int. Congr. Ser. 51,153 (1962).Google Scholar
  164. [164]
    Halleb, J. Reversibility of gestagen-induced gonadotrophs inhibition in guinea-pigs. Proceed ings of the biological sessions at the IPPF Conference Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,455 (1964).Google Scholar
  165. [165]
    Halleb, J. Die medikamentöse Hemmung der Ovulation. Referat 4. Tagung der Bayerischen, österreichischen und Schweizer Gesellschaft für Geburtshilfe u. Gynäkologie, 4. 10. 1963,Luzern. Fortsehr. Geburtsh. Gynäk. 21,37 (1965).Google Scholar
  166. [166]
    Halleb, J. Klinische und tierexperimentelle Testierung neuer synthetischer Gestagene. Fort sehr. Med. 82,529 (1964).Google Scholar
  167. [167]
    Halleb, J. Referat: Homonale Kontrazeption in Deutschland; und Rundtischgespräch über hormonale Kontrazeption und deren Nebenerscheinungen. 13. Kongr. ärztl. Fortbildg., 22. 5. 1964,Berlin. Berl. Ärztebl. 11,190 (1964).Google Scholar
  168. [168]
    Haller, J.: Aussprache zu Vortrag von O. Guhr : Kolposkopische, cytologische und istho- logisehe Portiobefunde bei ovulationshemmenden Medikamenten. Arch, für Gynäk. 202,218 (1965).Google Scholar
  169. [169]
    Haller, J. Ovulationshemmung durch Hormone, Monographie, 2. verb. Aufl. Stuttgart: Georg Thieme 1968.Google Scholar
  170. [170]
    Haller, J. Thrombose und Hormonbehandlung. Dtsch. med. Wschr. 90,2124 (1966).Google Scholar
  171. [171]
    Haller, J. The influence of long-term treatment with oral contraceptives on thyroid, adrenal, and liver. Proceed. The Pord Found. Int. Conf. on the physiology of human reproduction, Venice, p. 34 (1966).Google Scholar
  172. [172]
    Haller, J. Indikationen zur Behandlung mit den sogenannten Ovulationshemmern. Dtsch. med. Wschr. 91,1653 (1966).PubMedCrossRefGoogle Scholar
  173. [173]
    Haller, J. Mechanism of action of antifertility agents. In: C. Cassano (ed.), Research on steroids, vol. II, p. 379. Rom: II Pensiero Scientifico 1966.Google Scholar
  174. [174]
    Haller, J., u. H. Kirchhofe : Zur Frage der Kontrazeption. Teil II. Hormonale Kontrazeption. Internist (Berl.) 6,242 (1964).Google Scholar
  175. [175]
    Haller, J. A. König u. H. Poliwoda: Hormonausscheidung und Blutgerinnungsfaktoren unter oraler Gestagen-Östrogenbehandlung (Beurteilung des Thrombophlebitisrisikos). Geburtsh. u. Frauenheilk. 25,215 (1965).Google Scholar
  176. [176]
    Haller, J. R. Zichel u. H. U. Pixberg: Veränderungen des J-131-Trijodthyronintestes unter Hormonbehandlung und bei Störungen der Schwangerschaft. Geburtsh. u. Frauenheilk. 26,624 (1966).Google Scholar
  177. [177]
    Halter, G., G. Mestwerdt, C. Müller, K. Podleschka, W. Riffart u. H. Siebke : Umfrage über orale Antikonzeptions-Mittel. Münch, med. Wschr. 106,1113 (1964).Google Scholar
  178. [178]
    Harmsen, H., u. G. Fromm: Physiologische Möglichkeiten einer zeitweiligen Beschrän kung der Empfängnisfähigkeit. Med. Welt 1960,354.Google Scholar
  179. [179]
    Hass, T.: Experience with Provest in private practice. Int. J. Fertil. 8,743 (1963).PubMedGoogle Scholar
  180. [180]
    Hauser, G. A.: Praktische Erfahrungen mit Ovulationshemmern. Fortsehr. Geburtsh. Gynäk. 21,123 (1965).Google Scholar
  181. [181]
    Hauser, G. A. Contraceptive methods practiced among the population of central Switzerland. Proceed. The Ford Found. Int. Conf. on the physiology of human reproduction, Venice, p. 37 (1966).Google Scholar
  182. [182]
    Hauser, G. A., and M. Girotti: The menstrual cycle after oral contraception. Proceed. The Ford. Found. Int. Conf. on the physiology of human reproduction, Venice, p. 36 (1966).Google Scholar
  183. [183]
    Hauser, G. A., u. V. Schubiger: Nebenerscheinungen der ovulationshemmenden Präparate. Arch. Gynäk. 202,175 (1965).CrossRefGoogle Scholar
  184. [184]
    Hauser, G. A., u. V. Schubiger Why do women discontinue the pill ? Proceed. The Ford Found. Int. Conf. on the physiology of human reproduction, Venice, p. 36 (1966).Google Scholar
  185. [185]
    Hecht-Lucari, G.: Über die gegenseitige Beeinflussung von Progesteron und Äthinyl- Nortesteron. Experimenteller Beitrag. 6. Sympos. dtsch. Ges. Endokrin., Kiel 1959,S. 53. Berlin-Göttingen-Heidelberg: Springer 1960.Google Scholar
  186. [186]
    Hecht-Lucari, G. Fertilitätshemmende und nichthemmende orale Gestagene. Beitrag zur Fertilität und Sterilität, S. 89. Stuttgart: Ferdinand Enke 1964.Google Scholar
  187. [187]
    Hecht-Lucari, G. Central and peripheral action of fertility-inhibiting progestogens. Int. J. Fertil. 9,205 (1964).PubMedGoogle Scholar
  188. [188]
    Hecht-Lucari, G. H. G. Kraft, and H. Kieser: Estrogenic, antiestrogenic and antifertility activity of Chlormadinone acetate and other steroidal and non-steroidal compounds. In: C. Cassano (ed.), Research on steroids, vol. II, p. 357. Rom: II Pensiero Scientifico 1966.Google Scholar
  189. [189]
    Heckmann, U.: Zur Wirkung des Norhydroxyprogesteroncapronat auf das Adeno carcinoma corporis uteri in der Gewebekultur. Dtsch. med. Wschr. 90,2328 (1965).PubMedCrossRefGoogle Scholar
  190. [190]
    Hengstmann, H., u. D. Klien : Der Einfluß der weiblichen Sexualhormone auf die Faktoren des Prothrombinkomplexes und den Gerinnungsvorgang. Dtsch. Arch, klin. Med. 205,561 (1959).Google Scholar
  191. [191]
    Herrmann, U.: Zur gestagenen Wirkung von 6-Chlor-Aeetoxy-progesteron. Gynaecologia (Basel) 155,87 (1962).Google Scholar
  192. [192]
    Hertz, R.: Some unresolved problems connected with the use of oral contraceptive agent. Proceed. The Ford Foundation Int. Conf. on the physiology of human reproduction, Venice, p. 38 (1966).Google Scholar
  193. [193]
    Hillemanns, H. G., J. E. Ayre u. J. M. Le Guerrier: Die Einwirkung von Steroiden auf Krebsvorstadien an der Cervix. Arzneimittel-Forsch. 14,784 (1964).Google Scholar
  194. [194]
    Hoagland, H.: Endocrine control of fertility. Mod. Med. (Minneap.) 15,306 (1960).Google Scholar
  195. [195]
    Hohlweg, W.: Über die Bedeutung der Regulation der peripheren Hormondrüsen im Hinblick auf eine praktische Hormontherapie. Dtsch. Gesundh.-Wes. 8,245 (1956).Google Scholar
  196. [196]
    Hohlweg, W., u. G. Reiffenstuhl: Langzeitbehandlung mit Hormonen in der Gynäkologie. Wien. klin. Wschr. 77,878 (1965).PubMedGoogle Scholar
  197. [197]
    Hohlweg, W., u. G. Reiffenstuhl : LH-Secretion before, during and after treatment with ovulation inhibitors. Acta endocr. (Kbh.) 100,203 (1965).Google Scholar
  198. [198]
    Hohlweg, W., G. Reiffenstuhl, u. J. Schmor: Auslösung der Ovulation durch Gonadotropine, Hemmung der Ovulation durch Gestagene. Fortsehr. Geburtsh. Gynäk. 21,14 (1965).Google Scholar
  199. [199]
    Hollander, C. S., A. Garcia, S. H. Sturgis, and H. A. Selenkow: Effect of norethynodrel on thyroid. Mod. Med. (Minneap.) 31,82 (1963).Google Scholar
  200. [200]
    Hollander, C. S., A. Garcia, S. H. Sturgis, and H. A. Selenkow: Effect of an ovulatory suppressant on the serum protein-bound iodine and the red-cell uptake of radioactive tri-iodothyronine. New Engl. J. Med. 269,501 (1963).PubMedCrossRefGoogle Scholar
  201. [201]
    Holmes, R. L., and A. M. Mandl: Oral contraceptives, an assessment of their mode of action. Lancet 19621,1174.Google Scholar
  202. [202]
    Holmstrom, E. G.: The long-term use of ovulen for contraception. Metabolism 14,444 (1965).PubMedCrossRefGoogle Scholar
  203. [203]
    Hood, W. E., and W. L. Bond: Enovid therapy for premenstrual tension. Obstet, and Gynee. 14,239 (1959).Google Scholar
  204. [204]
    Hotjgie, C., R. N.Rutherford, A. L. Banks, and W. A. Coburn: Effect of a progestin - estrogen oral contraceptive on blood clotting factors. Metabolism 14,411 (1965).CrossRefGoogle Scholar
  205. [205]
    Huggins, O.: Hormonabhängige Geschwülste - klinisch und experimentell. Klin. Wsehr. 36,1102 (1958).CrossRefGoogle Scholar
  206. [206]
    Hutcherson, W. P., H. A. Schwartz, and W. Weathers: Long-term study of oral contraception with norethindrone 2 mg and mestranol 0,1 mg. Pertil. and Steril. 17,59 (1966).Google Scholar
  207. [207]
    I.P.P.F.: Medical handbook, 2nd ed. Paul & Mathew Ltd. 1965.Google Scholar
  208. [208]
    Ijzerman, G. L., M. N. G. Dukes u. H. Kopera: Klinische Ergebnisse der Fertilitätskontrolle nach cyclischer Anwendung von Lynestrenol in Kombination mit einem Oestrogen. Arzneimittel-Forsch. 13,507 (1963).Google Scholar
  209. [209]
    Jackson, M. C. N.: Methods of contraception. Practitioner 185,152 (1960).PubMedGoogle Scholar
  210. [210]
    Jackson, M. C. N.: Oral contraception in practice. J. Reprod. Fertil. 6,153 (1963).PubMedCrossRefGoogle Scholar
  211. [211]
    Jackson, M. C. N., and R. Linn: Optimum dosage for estrogen-progestogen balance to inhibit ovulation. Int. J. Fertil. 9,75 (1964).PubMedGoogle Scholar
  212. [212]
    Jacobson, B. D.: Hazards of norethindrone therapy during pregnancy. Amer. J. Obstet. Gynec. 84,962 (1962).Google Scholar
  213. [213]
    Jacobziner, H., and H. W. Raybin: Accidental chemical poisonings. N.Y. St. J. Med. 63,2846 (1963).Google Scholar
  214. [214]
    Johannisson, E., K. G. Tillinger, and E. Diczfalusy: Effect of oral contraceptives on the ovarian reaction to human gonadotrophins in amenorrhoeic women. Fertil. and Steril. 16,292 (1965).Google Scholar
  215. [215]
    Junkmann, K.: Experimentelle Gesichtspunkte bei der Prüfung synthetischer Gesta gene. Dtsch. med. Wsehr. 88,629 (1963).CrossRefGoogle Scholar
  216. [216]
    Junkmann, K. Die tierexperimentelle Prüfung antikonzeptioneller Steroide. Internist (Berl.) 5,238 (1964).Google Scholar
  217. [217]
    Käser, O.: Systemic effects of oral contraceptives. Proceed. The Ford Foundation Int. Conf. on the physiology of human reproduction, Venice, p. 44 (1966).Google Scholar
  218. [218]
    Kaiser, R.: Die Wirkung von Gestagenen beim Corpus-Carcinom. Arch. Gynäk. 193,195 (1958).Google Scholar
  219. [219]
    Kaiser, R. Der eytologische Effekt verschiedener gestagener Substanzen. 6. Symposion deutsche Ges. Endokrin., Kiel 1959,S. 64. Berlin-Göttingen-Heidelberg: Springer 1960.Google Scholar
  220. [220]
    Kaiser, R. The inhibition of ovulation with oral progestative substances. Int. J. Fertil. 9,87 (1964).PubMedGoogle Scholar
  221. [221]
    Kaiser, R. Hormonale Ovulationshemmung. Beiträge zur Fertilität und Sterilität, S. 87. Stuttgart: Ferdinand Enke 1964.Google Scholar
  222. [222]
    Kaiser, R. Vorverlegung, Verzögerung und Hemmung der Ovulation. Verh. 35. Tagg Dtsch. Ges. Gyn. München 1964. Arch. Gynäk. (im Druck).Google Scholar
  223. [223]
    Kaiser, R., u. U. Mohr: Zur Frage der Wirkung von Äthinylnortestosteronazetat auf das Wachstum bestimmter Sarkome. Z. Krebsforsch. 64,122 (1961).PubMedCrossRefGoogle Scholar
  224. [224]
    Kanematsu, S. H., and Ch. H. Sawyer: Blockade of Ovulation in Rabbits on hypo thalamic implants of norethindrone. Endocrinology 76,686 (1965).CrossRefGoogle Scholar
  225. [225]
    Kaufmann, C.: Progesteron, sein Schicksal im Organismus und seine Anwendung in der Therapie. Klin. Wsehr. 33,345 (1955).CrossRefGoogle Scholar
  226. [226]
    Kelley, R. M., and W. H. Baker: Progestational agents in the treatment of carcinoma of the endometrium. New Engl. J. Med. 264,216 (1961).PubMedCrossRefGoogle Scholar
  227. [227]
    Kennedy, B. J.: A Progestogen for treatment of advanced endometrial cancer. J. Amer. med. Ass. 184,758 (1963).CrossRefGoogle Scholar
  228. [228]
    Kepp, R.: Orale Antikonzeption mit Hormonpräparaten. Landarzt 38,206 (1962).Google Scholar
  229. [229]
    Kincl, F. A. : Notiz über den Mechanismus der Anti-Ovulation mit 6-Chloro-J-6–17a- Aeetoxyprogesteron in Kaninchen. Endokrinologie 44,67 (1963).PubMedGoogle Scholar
  230. [230]
    Kirchhoff, H. : Sind männliche Hormonpräparate schon heute für die gynäkologische Praxis zu empfehlen ? (Einfluß des Erugon und Testoviron auf das weibliehe Genitale der Maus und des Kaninchens). Geburts. u. Frauenheilk. 2,572 (1940).Google Scholar
  231. [231]
    Kirchhoff, H. Können bei vorübergehend bettlägerigen Patientinnen weiter verordnete Kontra zeptiva eine Hyperkoagulabilität des Blutes bedingen ? Dtsch. med. Wschr. 91,187 (1966).Google Scholar
  232. [232]
    Kirchhoff, H. Hormonal treatment with oral contraceptives. Proceed. Fifth conference of I.P.P.F. Europe and Near East Region 1966.Google Scholar
  233. [233]
    Kirchhoff, H., u. J. Haller: Konzeptionsverhütung durch oral wirksame Gestagene, ein aktuelles Problem. Dtsch. med. Wschr. 84,49 (1959).Google Scholar
  234. [234]
    Kirchhoff, H., u. J.Haller, Ist die orale Empfängnisverhütung mit Gestagenen unschädlich ? Med. Klin. 56,290 (1961).Google Scholar
  235. [235]
    Kirchhoff, H., u. J.Haller, Klinische Erfahrungen mit einer ovulationsunterdrückenden Östrogen-Gestagen- Kombination (Anovlar). Med. Klin. 59,681 (1964).PubMedGoogle Scholar
  236. [236]
    Kirchhoff, H., u. J.Haller, Hormonale Ovulationshemmung, Referat Therapiekongreß Karlsruhe. Therapie woche 14,33 (1964).Google Scholar
  237. [237]
    Kirchhoff, H., u. J.Haller, Zur Verordnung von Ovulationshemmern. Niedersächs. Ärzteblatt 37,315 (1964).Google Scholar
  238. [238]
    Kirchhoff, H., and H. Poliwoda: Observations of the blood coagulation mechanism in patients treated with an oral fertility controlling agent (Anovlar-Schering). Proc. 7th Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,341 (1964).Google Scholar
  239. [239]
    Kistner, R. W. : Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer (Philad.) 12,1106 (1959).CrossRefGoogle Scholar
  240. [240]
    Kloss, W.: Erfahrungen mit einem niedrig dosierten Gestagen-Östrogen-Gemiseh zur Ovulationshemmung. Med. Klin. 60,1029 (1965).PubMedGoogle Scholar
  241. [241]
    Knowles, E.: Oral contraceptive trial in the Fiji islands. Practitioner 196,551 (1966).PubMedGoogle Scholar
  242. [242]
    Kobayashi, T., Y. Yeda, S. Matsxjmoto, N. Ishizuka, and Taktjro Kobayashi: Oral contraception. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,345 (1964).Google Scholar
  243. [243]
    Köker, H., u. H. Habermann: Erfahrungen mit dem niedrig dosierten Gestagen-Östrogen-Gemisch Etaiontin als Antikonzeptivum in der geburtshilflich-gynäkologischen Fachpraxis. Z. ärztl. Fortbild. 54,8 (1965).Google Scholar
  244. [244]
    Köpera, H., M. Dtjkes, and G. Ijzermann: Critical evaluation of clinical data on Lyndiol. Int. J. Fertil. 9,69 (1964).PubMedGoogle Scholar
  245. [245]
    Köpera, H., u. G. L. Ijzerman : Über Erfahrungen mit einer neuen ovulationshemmenden Kombination von Lynestrenol raid Mestranol. Ther. d. Gegenw. 103,657 (1964).Google Scholar
  246. [246]
    Krüskemper, H. L. : Structure-activity-relations of neutral steroids concerning their influence on liver function as measured by multiple parameters including blood coagulation factors. In: C. Cassano (ed.), Research on steroids, vol. II, p. 489. Rom: Il Pensiero Scientifico 1966.Google Scholar
  247. [247]
    Kühne, D. : Klinische Erfahrungen mit Ovosiston zur Ovulationshemmunsr. Dtsch. Gesundh.-Wes. 8,377 (1966).Google Scholar
  248. [248]
    Kümmel, J. : Beeinflussimg der Akne vulgaris durch Ovulationshemmer. Med. Welt 1966,138. Ref. Geburtsh. u. Frauenheilk. 9,1325 (1966).Google Scholar
  249. [249]
    Kuppermann, H. S. : Gonadotropic-inhibiting and uterotropic effects of Enovid. Proc. Symp. 19-Nor Progestational Steroids, Chicago, Searle Res. Lab., p. 32 (1957).Google Scholar
  250. [250]
    Kuppermann, H. S. Use of new progestational hormones. Fed. Proc. 18,1071 (1959).Google Scholar
  251. [251]
    Kuppermann, H. S., and J. A. Epstein : Gonadotropic-inhibiting and uterotropic effects of Enovid. Proc. 19-Nor Progestational Steroids, Chicago, Searle Res. Lab., p. 32 (1957).Google Scholar
  252. [252]
    Langecker, H. : Abspaltung von Acetvlen und Bildung von 17-Ketosteroiden aus 17a-Äthinyl-Nortestosteron und 17a-Athinyl-3,17ß-Östradiol durch Einwirkung von Alkali. Naturwissenschaften 46,601 (1959).CrossRefGoogle Scholar
  253. [253]
    Larsson-Cohn, U.: Oral contraception and liver-function tests. Brit. med. J. 19651,No 5447,1414.Google Scholar
  254. [254]
    Larsson-Cohn, F., and U. Stenram : Jaundice during treatment with oral contraceptive agents. J. Amer. med. Ass. 193,422 (1965).CrossRefGoogle Scholar
  255. [255]
    Laitritzen, C.: Effects of lynestrenol-methoxyethinyl-estradiol and of norethisterone acetate ethinylestradiol on the ovarian cycline function and on the endogenous hormone secretion. In: C. Cassano (ed.), Research on steroids, vol. II, p. 421. Rom: Il Penciero Scientifico 1966.Google Scholar
  256. [256]
    Latjweryns, J., and J. Ferin: Effects on the ovary of prolonged administration of Lynestrenol: A histological study. Int. J. Fertil. 9,35 (1964).Google Scholar
  257. [257]
    Layne, D. S., and C. J. Meyer: Effects of 19-Norsteroids on plasma-protein binding of hormones. Metabolism 14,429 (1965).PubMedCrossRefGoogle Scholar
  258. [258]
    Layne, D. S., T. Golab, K. Arai, and G. Pincus: The metabolic fate of orally administered 3H-Norethynodrel and 3H-Norethindrone in humans. Biochem. Pharmacol. 12,905 (1963).PubMedCrossRefGoogle Scholar
  259. [259]
    Layne, D. S., C. J.Mayer, P. S. Vaishwanar, and G. Pincus : The secretion and metabolism of Cortisol and aldosterone in normal and steroid-reated women. J. clin. Endocr. 22,107 (1962).PubMedCrossRefGoogle Scholar
  260. [260]
    Lewis, J. M.: Clinical experience with norethynodrel and norethisterone as oral con traceptives. Proe. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Exeerpta med. (Amst.), Int. Congr. Ser. 72,379 (1963).Google Scholar
  261. [261]
    Linthorst, G.: Hepatic impairment during the intake of contraceptive pills: Clinical trial with postmenopausal women. Brit. med. J. 1964II, No 5406,426.Google Scholar
  262. [262]
    Livingston, N. B.: Medroxyprogesterone acetate and estrogen to inhibit fertility. Int. J. Fertil. 8,699 (1963).PubMedGoogle Scholar
  263. [263]
    Loraine, J.: The effect of anti-ovulatory compounds on hormone excretion. Int. J. Fertil. 9,155 (1964).PubMedGoogle Scholar
  264. [264]
    Loraine, J. A., E. T.Bell, R. A.Harkness, E. Mears, and M. Jackson: Hormone excretion patterns during and after the long-term administration of oral contraceptives. Acta endocr. (Kbh.) 50,15 (1965).Google Scholar
  265. [265]
    A. L. Herbst, and M. Krishnamtjrti: The effect of long-term therapy with oral contraceptives on gonadotropin and steroid excretion. Proceed. The Ford Foundation Int. Conf. on the physiology of human reproduction, Venice, p. 48 (1966).Google Scholar
  266. [266]
    A. L. Herbst, and J. B. Brown: A method for the quantitative determination of gonadotrophins in the urine of non-pregnant human subjects. J. Endocr. 18,77 (1959).CrossRefGoogle Scholar
  267. [267]
    Lxjdwig, H.: Gerinnungsphysiologische Untersuchungen im Zyklus der geschlechts reif en Frau und unter kontrazeptiver Medikation (Anovlar). Beiträge zur Fertilität und Sterilität, S. 116. Stuttgart: Ferdinand Enke 1964.Google Scholar
  268. [268]
    A. L.Herbst, Hämatologische und hämostaseologische Befunde bei der Ovulationshemmung durch Östrogen-Gestagen-Kombinationen. Fortsehr. Geburtsh. Gynäk. 21,198 (1965).Google Scholar
  269. [269]
    Lunenteld, B.: The ovarian response to exogenous human gonadotropins alone and during simultaneous administration of progestogens. Int. J. Fertil. 9,167 (1964).Google Scholar
  270. [270]
    Mass, J. M.: Withdrawal and breakthrough bleeding patterns attendant upon the use of certain aeetoxy progesterones. West. J. Surg. 71,224 (1963).Google Scholar
  271. [271]
    Macnaughton, M. C., and A. D. T. Go van: Ovarian effects of a new Oestrogen-Gestagen compound. In: C. Cassano (ed.), Research on steroids, vol.11,p. 431. Rom: II Pensiero Scientifieo 1966.Google Scholar
  272. [272]
    Mall, M., M. Arnold, St. Cloeren, E. More, R. H. H.Richter, Fr. Roth, H. Stamm u. H. Wyss : Vorläufige Resultate vergleichender Versuche mit oralen Kontrazeptiva, 1. Teil. Verh. Jahresversamml. der Schweiz. Gesellschaft f. Gynäkologie, Juni 1966,Lugano.Google Scholar
  273. [273]
    Mall-Haeeeli, M., K. S.Ludwig, M. Keller u. St. Cloeren: Beitrag zum Wirkungs mechanismus der oralen Ovulationshemmer beim Menschen. Gynaeeologia (Basel) 160,269 (1965).Google Scholar
  274. [274]
    Mammen, E. F., N. Aoki, A. C.Oliveira, M. I. Barnhart, and W. H. Seegers: Provest and blood coagulation tests. Int. J. Fertil. 8,653 (1963).PubMedGoogle Scholar
  275. [275]
    Manautou, J. M., M. Maqueo, R. A. Gilbert, and J. W. Goldzieher: Human endometrial activity of several new derivatives of 17-aeetoxyprogesterone. Fertil. and Steril. 13,169 (1962).Google Scholar
  276. [276]
    Maneschc, M., E. Cittadini, and P. Quartararo : The influence of estro-progestational treatments on the thyroid function. Exeerpta med. (Amst.), Int. Congr. Ser. 111,350 (1966).Google Scholar
  277. [277]
    Maqueo, M., C. Becerra, H. Munguia, and J. W. Goldzieher: Endometrial histology and vaginal cytology during oral contraception with sequential estrogen and progestin. Amer. J. Obstet. Gynee. 90,395 (1964).Google Scholar
  278. [278]
    Maqueo, M., E. Perez-Vega, J. W.Goldzieher, J. Martinez-Manautou, and H. Rudel: Comparison of the endometrial activity of 3 synthetic progestins used in fertility control. Amer. J. Obstet. Gynec. 85,427 (1963).PubMedGoogle Scholar
  279. [279]
    Margulies, R. R., J. L.Ambrus, I. B. Mink, and J. C. Stryker: Progestational agents and blood coagulation. Amer. J. Obstet. Gynec. 93,161 (1965).Google Scholar
  280. [280]
    Martinez-Manautou, J., V. Cortez, J. Giner, R. Aznar, J. Casasola, and H. W. Rudel: Low doses of progestogen as an approach to fertility control. Fertil. and Steril. 17,49 (1966).Google Scholar
  281. [281]
    Martini, L., and F. Fraschini : A new approach to the study of the mechanism of action of antiovulatory steroids. In: C. Cassano (ed.), Research on steroids, vol. II, p. 371. Rom: II Pensiero Scientifieo 1966.Google Scholar
  282. [282]
    Massenbach, W. v. : Über die unzweckmäßige Anwendung von Corpus-luteum-Hornion. Dtsch. med. Wschr. 07,513 (1941).Google Scholar
  283. [283]
    Matsumoto, S., T. Ito u. S. Inoije: Untersuchungen der ovulationshemmenden Wir kung von 19-Norsteroiden an laparotomierten Patientinnen. Geburtsh. u. Frauenheilk. 20,250 (1960).Google Scholar
  284. [284]
    Matsumoto, S. M., I. Sato, T. Ito, and A. Matsuoka: Electroencephalographic changes during long term treatment with oral contraceptives. Int. J. Fertil. 11,195 (1966).PubMedGoogle Scholar
  285. [285]
    Mattern, L.: Verlauf der Lungentuberkulose unter gleichzeitiger Behandlung mit Ovulationshemmern. Persönl. Mitt., November 1964.Google Scholar
  286. [286]
    Mazza, U., A. Cravario, L. Fiorina e V. Prato : Rapporti tra porfiria e gravidanza. Minerva med. 55,3967 (1964).PubMedGoogle Scholar
  287. [287]
    McGinty, D. A., and C. Djerassi: Some chemical and biological properties of 19-nor- 17a-ethynyltestosterone. Ann. N.Y. Acad. Sei. 71,500 (1958).CrossRefGoogle Scholar
  288. [288]
    McGovern, J. J., J. P.Bunker, R. Goldstein, and J. W. Estes : Effect of con jugated estrogens on the coagulation mechanism. J. Amer. med. Ass. 175,1011 (1961).CrossRefGoogle Scholar
  289. [289]
    McGowan, L.: Venous thrombophlebitis associated with the use of norethynodrel. Amer. J. Obstet. Gynec. 86,923 (1963).PubMedGoogle Scholar
  290. [290]
    McIntyre, N., M. J. Phillips, and J. C. Voigt: Two cases of thromboembolic disease associated with oral contraceptives. Brit. med. J. 1962 II, 1029.CrossRefGoogle Scholar
  291. [291]
    McWilliam, R. S., A. J. McDonald, and I. Lindsay: Thrombophlebitic following the use of norethynodrel (Enovid). Canad. med. Ass. J. 88,1032 (1963).PubMedGoogle Scholar
  292. [292]
    Mears, E.: Trial of oral contraceptives. Lancet 1960 I, 491.CrossRefGoogle Scholar
  293. [293]
    Mears, E. Clinical trials of oral contraceptives. Brit. med. J. 1961 II, 1179.CrossRefGoogle Scholar
  294. [294]
    Mears, E. Oral contraceptives. Results of large scale clinical trials. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,347 (1963).Google Scholar
  295. [295]
    Mears, E. Ovulation inhibitors. Family Planning 12,61 (1963).Google Scholar
  296. [296]
    Mears, E. A new type of oral contraceptives. Brit. med. J. 1963 I, 1318.CrossRefGoogle Scholar
  297. [297]
    Mears, E. New oral contraceptives. Correspondence. Brit. med. J. 1963 II, 558.Google Scholar
  298. [298]
    Mears, E. Ovulation inhibitors: Large-scale clinical trials. Int. J. Fertil. 9,1 (1964).PubMedGoogle Scholar
  299. [299]
    Mears, E. Handbook on oral contraception (edited for the oral advisory group of the medical committee of the I.P.P.F., p. 965. London: J. &. A. Churchill Ltd. 1965.Google Scholar
  300. [300]
    Mears, E. Comparison of combined and sequential oral contraceptives. Excerpta med. (Amst.), Int. Congr. Ser. III, 196 (1966).Google Scholar
  301. [301]
    Mears, E., and E. C. G. Grant: “Anovlar” as an oral contraceptive. Brit. med. J. 1962II, 75.Google Scholar
  302. [302]
    Mehring, W.: Einfluß der Ovulationshemmer auf Vaginalbild und Portioepithel. Med. Klin. 60,2016 (1965).PubMedGoogle Scholar
  303. [303]
    Trials with Enovid: Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,355 (1963).Google Scholar
  304. [304]
    Metcalf, M. G., and D. W. Beaven: Plasma-eorticosteroid levels in women receiving oral contraceptive tablets. Lancet 1963 II, No 7317,1095.CrossRefGoogle Scholar
  305. [305]
    Mey, R.: Zur Frage einer fetalen Maskulinisierung durch Progesteronbehandlung während der Gravidität. Beiträge zur Fertilität und Sterilität, S. 113. Stuttgart: Ferdinand Enke 1964.Google Scholar
  306. [306]
    Miller, Sh. P., St. L. Lee, and N. Ritz: Progestin-estrogen (SC 11800) therapy and the hemostatic mechanism - a controlled study. Metabolism 14,398 (1965).PubMedCrossRefGoogle Scholar
  307. [307]
    Mellman, N., and C. G. Hartman: Oral control of conception. Fertil. and Steril. 7,110 (1956).Google Scholar
  308. [308]
    Moghessi, K. S., A. Rosenthal, and N. Moss: Provera-ethinyl estradiol for control of conception. Int. J. Fertil. 8,703 (1963).Google Scholar
  309. [309]
    Morris, J. A.: Physiologic control of conception with norethynodrel. Amer. J. Obstet. Genyc. 82,428 (1961).Google Scholar
  310. [310]
    Moyer, D. L., E. T.Tyler, H. J. Olson, and L. Zeldis: Vaginal exfoliative cytology in patients receiving progestogens. In: G. L.Wied, Proc. of the First Int. Congr. of Exfoliative Cytology, p. 236. Wien 31. 6. 61. Philadelphia: Lippincott 1962.Google Scholar
  311. [311]
    Mueller, M. N., and A. Kappas: Estrogen pharmacology. I. The influence of estradiol and estriol on hepatic disposal of sulfobromophthalein (BSP) in man. J. clin. Invest. 43,1905 (1964).PubMedCrossRefGoogle Scholar
  312. [312]
    Müller, P. H.: Rezidivierende Lungenembolien mit sekundärer Thrombose der Pulmonalarterien bei Einnahme eines oralen Ovulationshemmers. Schweiz, med. Wschr. 95,1367 (1965).Google Scholar
  313. [313]
    Nelson, W. O.: Status of research on the physiologic control of fertility. Fertil. and Steril. 12,109 (1961).Google Scholar
  314. [314]
    Neyin, N. C., P. C. Elmes, and J. A. Weaver: Three cases of intravascular thrombosis occurring in patients receiving oral contraceptives. Brit. med. J. 19651,1586.Google Scholar
  315. [315]
    Ober, K. G.: Experimentelle Grundlagen der Progesteronbehandlung. 6. Sympos. dtsch. Ges. Endokrin., Kiel 1959,S. 76. Berlin-Göttingen-Heidelberg: Springer 1960.Google Scholar
  316. [316]
    Østergaard, E.: Inhibition of ovulation observed at laparotomy in patients treated with 6-dehydro-6-methyl-17a-acetoxyprogesterone (DMAP). Int. J. Fertil. 9,25(1964)Google Scholar
  317. [317]
    Østergaard, E., and J. Starup : Laparotomy observations during oral contraception. Proceed. Fifth Conf. I.P.P.F. Europe and Near East Region, Copenhagen (1966).Google Scholar
  318. [318]
    Østergaard, E. J.Arends, C. Hamburger, and S. G. Johnson: Postponement of menses, suppression of urinary gonadotrophs, 17-Kgs and 17-KS in normal women treated with a megastrol-acetate/mestranol combination (Delpregnin) from day 20 of the cycle. Acta endocr. (Kbh.), Suppl. 100,99 (1965).Google Scholar
  319. [319]
    Oldershausen, H. F. v., M. Eggstein, U. Dold u. K. Knörr: Ikterus bei intra hepatischer Cholestase nach Gaben von antikonzeptionellen Steroiden. Dtsch. med. Wsehr. 90,1290 (1965).CrossRefGoogle Scholar
  320. [320]
    Olson, H. J.: Fertility promoting and inhibiting effects of new steroid hormonal sub stances. J. Amer. med. Ass. 169,1843 (1959).CrossRefGoogle Scholar
  321. [321]
    Overbeek, G., and J. de Visser: Difficulties in determining the site of action of ovulation inhibitors. Int. J. Fertil. 9,177 (1964).PubMedGoogle Scholar
  322. [322]
    Palitz, L. L.: Abstract of a preliminary report on norethynodrel (Enovid) in the control of acne in the female. Arch. Derm. 86,237 (1962).CrossRefGoogle Scholar
  323. [323]
    Palmer, R.: Celioscopic study of women treated with cyclic norethisterone for endo metriosis. Int. J. Fertil. 9,121 (1964).PubMedGoogle Scholar
  324. [324]
    Palva, I. P., and O. O. Mustala: Oral contraceptives and liver damage. Brit. med. J. 1964 I, 688.CrossRefGoogle Scholar
  325. [325]
    Parkes, A. S.: Review of work with I.C.I. 33828: A nonsteroidal pituitary inhibitor. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Exeerpta med. (Amst.), Int. Congr. Ser. 72,493 (1963).Google Scholar
  326. [326]
    Paulsen, C. A., R. B.Leach, J. Lanman, N. Goldston, W. O. Maddock, and C. G. Heller: Inherent estrogenieity of noethindrone and norethynodrel: Comparison with other synthetic progestins and progesterone. Endocrinology 70,1033 (1962).Google Scholar
  327. [327]
    Pearson, O. H., and C. P. Rhoads: Hormones and cancer. Practitioner 182,687 (1959).PubMedGoogle Scholar
  328. [328]
    Peeters, F., R. Oeyen, and M. Van Roy: Ovarian inhibition with progestogens: A study of the recuperation stage. Int. J. Fertil. 9,111 (1964).PubMedGoogle Scholar
  329. [329]
    Peeters, F., M. van Roy u. H. Oeyen: Ovulationsunterdrückung durch Progestagene. Geburtsh. u. Frauenheilk. 20,1306 (1960).Google Scholar
  330. [330]
    Peeters, F., M. van Roy u. H. Oeyen: Klinische Erfahrungen über die Ovulationshemmung durch Gestagene. Med. Klin. 56,1679 (1961).PubMedGoogle Scholar
  331. [331]
    R. Oeyen, R. Snauwaert u. A. van Tilborg: Medizinische Indikationen zur Hemmung der Ovulation. Internist (Berl.) 5,246 (1964).Google Scholar
  332. [332]
    Pepper, H., and St. Lindsay: Levels of platelets and eosinophilic leukocytes during the normal menstrual cycle and the administration of norethynodrel (Enovid). Int. J. Fertil. 8,467 (1963).Google Scholar
  333. [333]
    Perlroth, M. G., H. S. Marver, and D. P. Tschudy: Oral contraceptive agents and the management of acute intermittent porphyria. J. Amer. med. Ass. 194,1037(1965)Google Scholar
  334. [334]
    Peterson, D. L., R. A. Edgren, and R. C. Jones: Steroid-induced block of ovarian compensatory hypertrophy in hemicastrated female rats. J. Endocr. 29,255 (1964).PubMedCrossRefGoogle Scholar
  335. [335]
    Peterson, W. F., M. W. Steel, and R. V. Coyne: Analysis of the effect of ovulatory suppressants on glucose tolerance. Amer. J. Obstet. Gynec. 95,484 (1966).PubMedGoogle Scholar
  336. [336]
    Phillips, L., R. N. Turksoy, and A. L. Southam: Influence of ovarian function on the fibrinolytic enzyme system. Amer. J. Obstet. Gynec. 82,1216 (1961).PubMedGoogle Scholar
  337. [337]
    Pilgeram, L. O.: Blood coagulability and oral contraception. Brit. med. J. 1964II, No 5387,883.Google Scholar
  338. [338]
    Pilgeram, L. O., and L. R. Pickart: Depression of plasma albumin by steroid therapy. Proc. Soc. exp. Biol. (N.Y.) 112,758 (1963).Google Scholar
  339. [339]
    Pincus, G.: Some effects of progesterone and related compounds upon reproduction and early development in mammals. Acta endocr. (Kbh.), Suppl. 28,18 (1956).Google Scholar
  340. [340]
    Pincus, G. Long term administration of Enovid to human subjects. Proc. of a Sympos. on 19-Nor Progestational Steroids, Chicago, Searle Res. Lab. 1957,p. 105.Google Scholar
  341. [341]
    Pincus, G.: The hormonal control of ovulation and early development. Postgrad. Med. 24,654 (1958).PubMedGoogle Scholar
  342. [342]
    Pincus, G.: Fertility control with oral medication. Stud. Fertil. 10,3 (1959).Google Scholar
  343. [343]
    Pincus, G. Progestational agents and the control of fertility. In: R. S.Harris, G. F.Marrian, K. Y.Thimann, Yitam. and Horm. 17,307 (1959).Google Scholar
  344. [344]
    Pincus, G. Fertility control by endocrine agents. Acta endocr. (Kbh.) 34,Suppl. 50,135 (1960).Google Scholar
  345. [345]
    Pincus, G. Clinical control of fertility. Advanc. Chemistry 44,177 (1964).CrossRefGoogle Scholar
  346. [346]
    Pincus, G. The control of fertility. New York: Academic Press 1965.Google Scholar
  347. [347]
    Pincus, G. M. C.Chang, M. X.Zarrow, E. S. E. Hafez, and A. Merrill: Studies of the biological activity of eertein 19-norsteroids in female animals. Endocrinology 59,695 (1956).PubMedCrossRefGoogle Scholar
  348. [348]
    Pincus, G., and C. R. Garcia: Studies on vaginal, cervical and uterine histology. Metabolism 14,344 (1965).PubMedCrossRefGoogle Scholar
  349. [349]
    Pincus, G., and C. R.Garcia, M. Paniagua, and J. Shepard : Ethynodiol diacetate as a new, highly potent oral inhibitor of ovulation. Science 138,439 (1962).Google Scholar
  350. [350]
    Pincus, G., C. R.Garcia, J. Rock, M. Paniagua, A. Pendleton, F. Laraque, R. Nicolas, R. Borno, and Y. Pean: Effectiveness of an oral contraceptive. Science 130,81 (1959).PubMedCrossRefGoogle Scholar
  351. [351]
    Pincus, G.,C. R.Garcia, J. Rock, M. C. Chang, and C.-R. Garcia: Effects of certain 19-nor steroids on reproductive processes and fertility. Fed. Proc. 18,1051 (1959).PubMedGoogle Scholar
  352. [352]
    Pincus, G.,C. R. Garcia, and C.-R. Garcia: Oral methods of fertility control: Field trials with norethy nodrel as an oral contraceptive. Proc. of the 6th Int. Conf. on Planned Parenthood, New Delhi 1959,p. 216.Google Scholar
  353. [353]
    E. Rice-Wray, M.Paniagua, and I. Rodriguez: Fertility control with oral medication. Amer. J. Obstet. Gynec. 75,1333 (1958).Google Scholar
  354. [354]
    Pochi, P. E., and J. S. Strauss: Lack of androgen effect on human sebaceous glands with low-dosage norethindrone. Amer. J. Obstet. Gynec. 93,1002 (1965).PubMedGoogle Scholar
  355. [355]
    Popper, H., u. F. Schaffner: Die Leber; Struktur und Funktion (Liver; structure and function). Deutsche Übersetzung und Bearbeitung von W. Eger und J. Haller. Stuttgart: Georg Thieme 1961.Google Scholar
  356. [356]
    Powell, L. Ch., M. M. Guest, and T. P. Bond : Coagulation and fibrinolytic studies in women receiving an anovulatory drug (medroxyprogesterone acetate with estradiol). Amer. J. Obstet. Gynec. 93,167 (1965).PubMedGoogle Scholar
  357. [357]
    Puccini, G.: Analysis of menstrual cycles in women treated with the sequential method. In: C. Cassano (ed.), Research on steroids, vol. II, p. 449. Rom: H Pensiero Scientific© 1966.Google Scholar
  358. [358]
    Puebla, R. A., A. Zarate, and R. B. Greenblatt: Ethynodiol diacetate: Clinical experience with a synthetic oral progestin. Fertil. and Steril. 16,805 (1965).Google Scholar
  359. [359]
    Pullen, D.: “Conovid-E” as an oral contraceptive. Brit. med. J. 1962II, 1016.Google Scholar
  360. [360]
    Pummer, M.: Erste Erfahrungen mit einem neuen oralen Antikonzeptivum. Landarzt 41,340 (1965).PubMedGoogle Scholar
  361. [361]
    Quick, A. J.: Oral contraception and coagulability. Brit. med. J. 19631,744.Google Scholar
  362. [362]
    Rauscher, H., u. A. Leeb : Beeinflussung der Ovulation. Fortsehr. Geburtsh. Gynäk. 21,165–170 (1965).Google Scholar
  363. [363]
    Reed, D. L., and W. W. Coon: Thromboembolism in patients receiving progestational drugs. New Engl. J. Med. 269,622 (1963).PubMedCrossRefGoogle Scholar
  364. [364]
    Reifenstein, E. C., Th. E.Pratt, K. A. Hartzell, and W. B. Shafer: Artificial menstrual cycles induced in ovulating women by monthly injection of progestogen- estrogen. Fertil. and Steril. 16,652 (1965).Google Scholar
  365. [365]
    Rice-Wray, E.: Oral contraception in Latin America. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,358 (1963).Google Scholar
  366. [366]
    Rice-Wray, E. Fertility after use of oral antiferitility agents and health of children born to these mothers. In: C. Cassano (ed.), Research on steroids, vol. II, p. 525. Rom. II Pensiero Scientifico 1966.Google Scholar
  367. [367]
    Rice-Wray, Q. E., A. Aranda-Rosell, M. Maqueo, and J. W. Goldzieher: Com parison of the long-term endometrial effects of synthetic progestins used in fertility control. Amer. J. Obstet. Gynec. 87,429 (1963).PubMedGoogle Scholar
  368. [368]
    Rice-Wray, E., S. Corren u. H. Gastelum: Erfahrungen mit dem oralen Kontra zeptivum Anovlar. Med. Klin. 61,11 (1966).Google Scholar
  369. [369]
    Rice-Wray, E., J. W. Goldzieher, and A. Aranda-Rosell: Oral progestions in fertility control: A comparative study. Fertil. and Steril. 14,402 (1963).Google Scholar
  370. [370]
    Rice-Wray, E., M. Schulz-Contreras, I. Guerrero, and A. Aranda-Rosell: Long-term ad ministration of norethindrone in fertility control. J. Amer. med. Ass. 180,355 (1962).CrossRefGoogle Scholar
  371. [371]
    Rice-Wray, E., A. Carvantes, J. Gutierrez, A. Aranda-Rosell, and J. W. Goldzieher: The accep tability of oral progestins in fertility control. Metabolism 14,451 (1965).PubMedCrossRefGoogle Scholar
  372. [372]
    Richter, H. H.: Neure Perspektiven für die Kontrolle der Fertilität. Ther. Umsch. 22,542 (1965).PubMedGoogle Scholar
  373. [373]
    Richter, R. H. H., M. Arnold, M. Mall, F. Roth, H. Stamm, H. Wyss, St. Cloeren, and E. More: Comparative trials with oral contraceptives. Proceed. Converence on the physiology of Human Reproduction sponsored by the Ford Foundation, Venice, p. 56 (1966).Google Scholar
  374. [374]
    H. Wyss, St. Cloeren, and E. More: Comparative trials with five oral contraceptives. In: C. Cassano (ed.), Research on steroids, vol. II, p. 441. Rom: II Pensiero Seientifico 1966.Google Scholar
  375. [375]
    Richter, R. H. H., and W. E. Schreiner: Die temporäre hormonale Sterilisierung der Frau und ihre Problematik. Ther. Umsch. 20,489 (1963).PubMedGoogle Scholar
  376. [376]
    Rimington, C., and F. de Matteis : Oral contraceptives and acute intermittent porphyria. Lancet 19651,270.Google Scholar
  377. [377]
    Rizk allah, T. H., and M. L. Taymor: Ovulation inhibition with a longacting injectable. II. The cycling effects of varying progestagen-estrogen combinations. Amer. J. Obstet. Gynec. 94,161 (1966).Google Scholar
  378. [378]
    Robinson, R. W., W. D. Cohen, and N. Higano : Clinical and serum lipid effects of a combination of norethynodrel plus ethynylestradiol 3-methyl ehter in postmenopausal women. Amer. J. med. Aci. 244,736 (1962).Google Scholar
  379. [379]
    Rock, J.: Inhibition of ovulation in the human. In: C. A.Villee, Control of ovulation. Proc. of the Conf. at Endicott House, Dedham, Mass., 1960,p. 222. New York: Pergamon Press 1961.Google Scholar
  380. [380]
    Rock, J. The time has come. New York: Hearst 1963.Google Scholar
  381. [381]
    Rock, J., C.-R. Garcia, J. McLeod, B. J. Pisani, and A. Southam: Fertility and infertility. Bull. N.Y. Acad. Med. 37,689 (1961).PubMedGoogle Scholar
  382. [382]
    Rock, J., C.-R. Garcia, and G. Pincus: In: G. E.Pincus, Recent progr. in hormone. Res. 13,323 (1957).Google Scholar
  383. [383]
    Rock, J., C.-R. Garcia, and G. Pincus, Use of some progestational 19-norsteroids in gynecology. Amer. J. Obstet. Gynec. 79,758 (1960).PubMedGoogle Scholar
  384. [384]
    Roland, M., M. J.Clyman, A. Decker, and W. B. Ober: Classification of endometrial response to synthetic progestogen estrogen compounds. Fertil. and Steril. 15,143 (1964).Google Scholar
  385. [385]
    Roland, M., M. J.Clyman, A. Decker, and W. B. Ober: Segmential Endometrial alterations during one cycle of treatment with synthetic progestagen-estrogen compounds. Fertil. and Steril. 17,3 (1966).Google Scholar
  386. [386]
    Rubin, A.: New progesteronie hormones in the control of fertility. Penn. med. J. 65,581 (1962).PubMedGoogle Scholar
  387. [387]
    Rutherford, R. N., A. L. Banks, and W. A. Coburn: Deladroxate for the prevention of ovulation. Fertil. and Steril. 15,648 (1964).Google Scholar
  388. [388]
    Ryan, G. M., D. A. Goss, and D. E. Reid : Pituitary gonadotropins during long-term Enovid-therapy. Amer. J. Obstet. Gynec. 94,515 (1966).PubMedGoogle Scholar
  389. [389]
    Sala, G., and E. Castegnaro : Effect of a progestinic-estrogenic combination on human adrenal function. In: C. Cassano (ed.), Research on steroids, vol. II, p. 405. Rom: II Pelsiero Scientifico 1966.Google Scholar
  390. [390]
    de Salcedo, I., M. D.Carrington, J. L. Silva, and F. M. Fonseca Ferreira: Some aspects of thyroid, adrenal and liver function during longterm administration of antifertility agents to healthy women. In: C. Cassano (ed.), Research on steroids, vol. II, p. 493. Rom: II Pensiero Scientifico 1966.Google Scholar
  391. [391]
    Samuels, A. J., F. Lepowsky, and E. Tyler: Assay of selected hematologic and coagulation factors in patients on provera. Int. J. Fertil. 8,665 (1963).PubMedGoogle Scholar
  392. [392]
    Sas, M., M. Gabor, L. Kovacs, I. Nemeth u. F. E. Szontagh: Untersuchungen über die Gerinnungsfaktoren während der Gestagen-Behandlung. Arch. Gynäk. 199,641 (1964).CrossRefGoogle Scholar
  393. [393]
    Satterthwaite, A. P., and C. J. Gamble: Conception control with norethynodrel. J. Amer. med. Worn. Ass. 17,797 (1962).Google Scholar
  394. [394]
    Scarpellini, L.: Laboratory observations on the effects of three estrogen-progestin combinations on the human female genital tract. In: C. Cassano (ed.), Research on steroids, vol. II, p. 453. Rom: II Pensiero Scientifico 1966.Google Scholar
  395. [395]
    Schmelcher, R.: Die Verordnung sogenannter “Anti-Babypillen” in rechtlicher Sicht. Dtsch. med. Wsehr. 89,1522 (1964).Google Scholar
  396. [396]
    Schmidt-Elmendorff, H., u. H. Kopera: Der Einfluß von ovulationshemmenden Steroiden auf die FSH-LH- und Gesamtgonadotropin-Ausscheidung bei Frauen im gesehleehtsreifen Alter. Verhandl. 12. Sympos. Dtsch. Ges. f. Endokrinologie. Ber- lin-Heidelberg-New York: Springer 1966.Google Scholar
  397. [397]
    Schmidt-Elmendorff, H., u. H.Kopera, The effect of various antiovulatory compounds on the FSH, LH and “total gonadotrophin” excretion during the menstrual cycle. Proceedings Fifth World Congress on Fertility and Sterility Stockhom. Exeerpta med. (Amst.), Int. Congr. Ser. (im Druck.).Google Scholar
  398. [398]
    Schoceaert, J., and R. Mouunasse: Clinical observations with prolonged continuous administration of norethisterone acetate. Int. J. Fertil. 9,123 (1964).Google Scholar
  399. [399]
    Schöleb, H. F. L.: Anti-fertility effects with some retrosteroids in animal experiments. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Exeerpta med. (Amst.), Int. Congr. Ser. 72,439 (1963).Google Scholar
  400. [400]
    Schreiner, W. E.: Die medikamentöse Geburtenregelung mit den modernen Ovu lationshemmern. Z. Präv.-Med. 7,507 (1962).CrossRefGoogle Scholar
  401. [401]
    Schreiner, W. E. Die orale hormonale Antikonzeption. Zbl. Gynäk. 85,500 (1963).Google Scholar
  402. [402]
    Seegab-Jones, G.: Convention report (Am. College of Obstetr. and Gynevologists, Chicago). Prevention of conception. Mod. Med. (Minneap.) 30,9 (1962).Google Scholar
  403. [403]
    Segal, S. J., and W. O. Nelson: An orally active compound with antifertility effects in rats. Proc. Soc. exp. Biol. (N.Y.) 98,431 (1958).Google Scholar
  404. [404]
    Shafey, Sh., and P. Scheinberg : Neurological syndromes occurring in patients receiving synthetic steroids (oral contraceptives). Neurology (Minneap.) 16,205 (1966).Google Scholar
  405. [405]
    Shah, N. A., and J. C. Cobb : A preliminary report on the use of oral contraceptive pills synchronized with the phase of the moon. Proc. 7th Conf. Int. Planned Parenthood Fes., Singapore 1963. Exeerpta med. (A,st.), Int. Congr. Ser. 72,394 (1963).Google Scholar
  406. [406]
    Shearman, R. P.: Effects of the long-term use of ovulation inhibitors on the excretion of ovarian steroids. J. Reprod. Fertil. 5,457 (1963).Google Scholar
  407. [407]
    Siegel, P., u. G. Heinen: Die Reaktion des Endometriums auf die zyklische Behand lung mit Ovulationshemmern. Z. Geburtsh. u. Frauenheilk. 25,312 (1965).Google Scholar
  408. [408]
    Siegel, P., u. G.Heinen, Endometriumbefunde bei Ovulationshemmern. Arch. Gynäk. 202,248 (1965).CrossRefGoogle Scholar
  409. [409]
    Sobrero, A. J.: Field trial of Provest as contraceptive. Int. J. Fertil. 8,721 (1963).PubMedGoogle Scholar
  410. [410]
    Soost, H. J.: Kolposkopische, zytologische und histologische Portiobefunde unter ovulationshemmender Medikation. Münch, med. Wschr. 107,489 (1965).Google Scholar
  411. [411]
    Sorcini, G.: Effect of norethynodrel-mestranol on plasmatic and urinary levels of testosterone. In: C. Cassano (ed.), Research on steroids, vol. II, p. 417. Rom: II Pensiero Scientifieo 1966.Google Scholar
  412. [412]
    Sotaniemi, E., K. E. Kretjs, and T. M. Scheinin: Oral contraceptives and liver damage, correspondence. Brit. med. J. 19651,No. 5440,393.Google Scholar
  413. [413]
    Southam, A. L.: A clinical evaluation of the 19-nor steroids. Med. Sei. 5,258 (1959).Google Scholar
  414. [414]
    Spellacy, W. N., and K. L. Carlson : Plasma insulin and blood glucose levels in patients taking oral contraceptives. Amer. J. Obstet. Gynecol. g5,474 (1966).Google Scholar
  415. [415]
    Staemmler, H.-J.: Über die Behandlung mit synthetischen Gestagenen. Dtsch. med. J. 13,293 (1962).PubMedGoogle Scholar
  416. [416]
    Staemmler, H.-J., u. C. Lauritzen: Pharmakologie und klinische Anwendung des Äthinyl-Nor- Testosteron. Zbl. Gynäk. 754 (1958).Google Scholar
  417. [417]
    Statzer, D. E., S. L. Cohn, and W. S. Floyd: An evaluation of norethindrone 2 mg with mestranol 0.11 mg in control of conception. Vertil. and Steril. 17,250 (1966).Google Scholar
  418. [418]
    Steiner, G. J., R. W. Kistner, and J. M. Craig: Histolofical effects of progestins on hyperplasia and carcinoma in situ of the endometrium-further observations. Metabolism 14,356 (1965).CrossRefGoogle Scholar
  419. [419]
    Š těrba, R., A. Králova, J. Ulrych u. B. Valova: Die ersten klinischen Erfahrungen mit 16-Methylen-6-Dehydro-17α-Aeetoxyprogesteron (MDAP). Zbl. Gynäk. 87,540 (1965).Google Scholar
  420. [420]
    Stevens, Y. C., N. Yorys, P. K. Besch, and R. D. Barry: The effects of a new oral contraceptive on gonadotropin excretion. Metabolism 14,327 (1965).PubMedCrossRefGoogle Scholar
  421. [421]
    Stoll, A., J. T.Andrews, R. Motteram, and J. Upfill: Oral contraceptives and liver damage. Brit. med. J. 1965 I, No 5436,723.CrossRefGoogle Scholar
  422. [422]
    Stollreiter, L.: Bestehen Bedenken gegen eine hormonelle Antikonzeptionsbehand- lung bei Epilepsie ? Dtsch. med. Wschr. 89,1856 (1964).Google Scholar
  423. [423]
    Strade, H. A.: Lyndiol: Evaluation of safety and efficacy as an oral contraceptive. Curr. ther. Res. 8,265 (1966).PubMedGoogle Scholar
  424. [424]
    Strauss, J. B., u. P. E. Pochi: Wirkung der zyklischen Gestagen-Östrogen-Therapie auf Talgsekretion und Akne bei der Frau. J. Amer. med. Ass. 190,815 (1964).CrossRefGoogle Scholar
  425. [425]
    Strauss, J. B., u. P. E.Pochi, Effect of Enovid on sebum production in females. Arch. Derm. 87,366 (1963).CrossRefGoogle Scholar
  426. [426]
    Street, H. S.: Lond-term ovulation control with oral synthetic progestin. Clin. Med. 69,435 (1962).PubMedGoogle Scholar
  427. [427]
    Suchowsky, G. K., u. G. Baldratti: Zur Frage des Mechanismus der Ovulations- hemmung und vergleichende Untersuchungen der ehemischen Struktur und biologischen Wirkung einiger Steroide. Beiträge zur Fertilität und Sterilität, S. 92. Stuttgart: Ferdinand Enke 1964.Google Scholar
  428. [428]
    Stjmner, C. F., and P. N. Baer: Clinical observations of gingiva of patients on nor- ethynodrel therapy. J. Periodont. 38,344 (1962).Google Scholar
  429. [429]
    Swaab, L. I.: A field trial on Lyndiol and Enovid. Proc. 7th Conf. Int. Planned Parent hood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,369 (1963).Google Scholar
  430. [430]
    Swaab, L.: A field trial with Lyndiol and Conovid. Int. J. Fertil. 9,107 (1964).PubMedGoogle Scholar
  431. [431]
    Swaab, L. I.: Oral contraceptives and liver damage. Brit. med. J. 1964,No 5411,755.CrossRefGoogle Scholar
  432. [432]
    Swaab, L. I. Enige Resultaten bij de toepassing van orale ovulatieremmers (orale articonceptie). Ned. T. Geneesk. 108,1070 (1964).PubMedGoogle Scholar
  433. [433]
    Swaab, L. I. Blood pressure and oral contraception. Excerpta med. (Amst.), Int. Congr. Ser. III, 198 (1966).Google Scholar
  434. [434]
    Swartz, D. P., J. H.Walters, E. R. Plunkett, and R. A. H. Kinch: Clinical experience with a new oral contraceptive. Fertil. and Steril. 14,320 (1963).Google Scholar
  435. [435]
    Swyer, G. I. M.: Oral contraceptives. Practitioner 190,155 (1963).Google Scholar
  436. [436]
    Swyer, G. I. M. Small9scale clinical trials of progestogens for control of conception. Int. J. Fertil. 9,11 (1964).PubMedGoogle Scholar
  437. [437]
    Swyer, G. I. M. The safety of oestrogen/progestagen oral contraceptives. Excerpta med. (Amst.), Int. Congr. Ser. 111,10 (1966).Google Scholar
  438. [438]
    Swyer, G. I. M., and V. Little : Absence of hepatic impairment in long-term oral contraceptive users. Brit. med. J. 1965 H, 1412.Google Scholar
  439. [439]
    Szontagh, F. E., u. M. Sas : Zur Frage der ovulationshemmenden Dosis oraler Gestagene. Zbl. Gynäk. 410 (1964).Google Scholar
  440. [440]
    Tait, A. S.: Oral contraceptives. Med. J. Aust. 52,667 (1965).Google Scholar
  441. [441]
    Takano, K., H. Yamamura, M. Suzuki, and H. Nishimura: Teratogenic effect of Chlormadinon acetate in mice and rabbits. Proc. Soc. exp. Biol. (N.Y.) 121,445 (1966).Google Scholar
  442. [442]
    Taymor, M. L., St. Planck, and Cl. Yahia: Ovulation inhibition with a longacting parenteral progestogen-estrogen combination. Fertil. and Steril. 15,657 (1964).Google Scholar
  443. [443]
    Tenyi, M., S. Sebök, F. E. Szontagh u. M. Földi: Zur Frage der Wirkung oraler Progestagene auf den Kohlenhydratstoffwechsel. Endokrinologie (1966) (im Druck).Google Scholar
  444. [444]
    Thiery, M.: Should genital candidosis be considered a side effect or oral contraception ? Proceed. Fifth Conf. I.P.P.F. Europe and Near East Region, Copenhagen (1966).Google Scholar
  445. [445]
    Tietze, K., u. W. Jaensch-Zander: Zur Frage einer kanzerogenen Wirkung der Ovulationshemmer. Dtsch. Ärztebl. 10,635 (1966).Google Scholar
  446. [446]
    Toaee, R., and R. Jewelewicz: Inhibition of lactogenesis by combined oral progesto gens and oestrogens. Lancet 1963 II, 322.Google Scholar
  447. [447]
    Toivakka, E.: Oral contraception in epileptics. Drug Res. (im Druck).Google Scholar
  448. [448]
    Topete, M. M., and E. Rice-Wray: The effect of estrogens, progestins and combina tions of estrogens and progestins on the human endometrium. In: C. Cassano (ed.), Research on steroids, vol. II, p. 463. Rom: II Pensiero Scientifico 1966.Google Scholar
  449. [449]
    Toth, F.: Über die klinische Bedeutung der synthetischen Progesteroide und ihre etwaige Rolle bei der Karzinogenese. Z. Geburtsh. Gynäk. 161,94 (1963).Google Scholar
  450. [450]
    Toth, F. The effect of synthetic progestogens on the ovaries. Int. J. Fertil. 9,151 (1964).PubMedGoogle Scholar
  451. [451]
    Toth, F. The inhibiting effect of a norsteroid on tumor formation and on the metabolism of tumor cells. Amer. J. Obstet. Gynee. 94,518 (1966).Google Scholar
  452. [452]
    Trampuz, V.: Limitations in use of contraceptives. In: C. Cassano (ed.) Research on steroids, vol. II, p. 439. Rom: II Pensiero Scientifico 1966.Google Scholar
  453. [453]
    Tscherne, E.: Zur Frage der Ovulationshemmung. Zbl. Gynäk. 84,1581 (1962).Google Scholar
  454. [454]
    Turksoy, R. N., L. Lang Phillips, and A. L. Southam: Influence of ovarian function on the fibrinolytic enzyme system. Amer. J. Obstet. Gynee. 82,1211 (1961).Google Scholar
  455. [455]
    Turpeinen, K.: Ovulation inhibition by Lyndiol: A clinical trial. Int. J. Fertil. 9,137 (1964).PubMedGoogle Scholar
  456. [456]
    Tyler, E. T.: The use of steroid substances as a clinical antifertility agents. Proc. of the 6th Int. Conf. on Planned Parenthood, NewDelhi 1959,p. 237.Google Scholar
  457. [457]
    Tyler, E. T. Norethinedrone in clinical antifertility studies. Acta endocr. (Kbh.) 35,Suppl. 51,933 (1960).Google Scholar
  458. [458]
    Tyler, E. T. Oral contraception. J. Amer. med. Ass. 175,225 (1961).CrossRefGoogle Scholar
  459. [459]
    Tyler, E. T. Comparative statistics on a variety of oral contraceptive preparations. Proc. 7th Conf. Int. Planned Parenthood Fed., Singapore 1963. Excerpta med. (Amst.), Int. Congr. Ser. 72,373 (1963).Google Scholar
  460. [460]
    Tyler, E.: Oral contraception and venous thrombosis. J. Amer. med. Ass. 185,131 (1963).CrossRefGoogle Scholar
  461. [461]
    Tyler, E. T.: Current status of oral contraception. J. Amer. med. Ass. 187,562 (1964).CrossRefGoogle Scholar
  462. [462]
    Tyler, E. T. Oral contraceptives and liver damage. Brit. med. J. 1964II, No 5419,1264.CrossRefGoogle Scholar
  463. [463]
    Tyler, E. T., and H. J. Olson: Clinical use of new progestational steroids in fetility. Ann. N.Y. Acad. Sei. 71,704 (1958).CrossRefGoogle Scholar
  464. [464]
    Tyler, E. T., and H. J. Olson: Fertility promoting and inhibiting effects of new steroid hormonal substances. J. Amer. med. Ass. 169,1843 (1959).CrossRefGoogle Scholar
  465. [465]
    Tyler, E. T., and H. J.Olson, L. Wolf, S. Finkelstein, J. Thayer, N. Kaplan, M. Leyin, and J. Weintraub : An oral contraceptive. A 4-year study of norethindrone. Obstet, and Gynec. 18,363 (1961).Google Scholar
  466. [466]
    Ufer, J.: Zur hormonalen Konzeptionsverhütung. Med. Ellin. 59,1089 (1964).Google Scholar
  467. [467]
    van de Kercebove, D. A.: An unusual endometrial response adter long-term admini stration of lynestrenol methoxyethinylestradiol. In: C. Cassano (ed.), Research on steroids, vol. II, p. 485. Rom: II Pensiero Scientifico 1966.Google Scholar
  468. [468]
    Vanek, R.: Ovarian inhibition with ethynodiol-diaeetate: Influence of steroidgenesis. Int. J. Fertil. 9,129 (1964).PubMedGoogle Scholar
  469. [469]
    Varga, A., and E. Henriksen: Clinical and histopathologic evaluation of the effect of 17-alpha-hydroxyprogesterone-17-n-caproate on endometrial carcinoma. Obstet, and Gynec. 18,658 (1961).Google Scholar
  470. [470]
    Varga, A., Effect of 17-alpha-Hydroxyprogesterone-17-n-caproate on various pelvic malignancies. Obstet, and. Gynec. 23,51 (1964).Google Scholar
  471. [471]
    Vasicka, A., and F. J. Richter: Effect of Enovid on the human ovary, endometrium and vaginal mears during the preovulatory phase. Surg. Forum 10,730 (1960).PubMedGoogle Scholar
  472. [472]
    Venning, G. R.: The influence of contraceptive practice upon maternal and child health. Metabolism 14. 457 (1965).PubMedCrossRefGoogle Scholar
  473. [473]
    Venning, G. R. Reduction in the birthrate in a community associated with the administration of oral contraceptives. In: C. Cassano (ed.), Research on steroids, vol. II, p. 435. Rom: II Pensiero Scientifico 1966.Google Scholar
  474. [474]
    Verhagen, A., u. H. Theman: Elektronenmikroskopische Endometriumbefunde nach Behandlung mit ovulationshemmenden Stoffen. Arch. Gynäk. 202,253 (1965).CrossRefGoogle Scholar
  475. [475]
    Vorys, N., J. C. Ullery, and V. Stephens: The effects of sex steroids on gonado- trophins. Amer. J. Obstet. Gynec. 93,641 (1965).PubMedGoogle Scholar
  476. [476]
    Wachtel, E.: Cytological patterns during administration of antifertility pills, with special reference to norethisterone acetate - ethinylestradiol, lynestrenol-mestranol and sequential therapy. In: C. Cassano (ed.), Research on steroids, vol. II, p. 459. Rom: II Pensiero Scientifico 1966.Google Scholar
  477. [477]
    Wade, Self L.: Pituitary cytology of rats receiving ethynodiol diacetate and mestranol for 2 years. Metabolism 14,311 (1965).CrossRefGoogle Scholar
  478. [478]
    Wagner, H.: Spezielle Untersuchungen über die neueren Gestagene. Münch, med. Wschr. 105,1517 (1963).Google Scholar
  479. [479]
    Wallach, E. E., C.-R. Garcia, R. W. Kistner, and G. Pinctts: Adrenal function during long-term Enovid administration. Amer. J. Obstet. Gynec. 87,991 (1963).PubMedGoogle Scholar
  480. [480]
    Walser, H., R. Margtjlis, and J. Ladd: Effects of prolonged administration of progestins on the endometrium and the function of the pituitary, thyroid and adrenal glands. Int. J. Fertil. 9,189 (1964).PubMedGoogle Scholar
  481. [481]
    Wattnick, A. S., J. Gibson, M. Vinerga, and S. Tolksdorf: The comparative contraceptive activities of 10β-hydroperoxy-17α-ethynyl-4-estren-17β-ol-3-one (Sch 10015) and norethynodrel. J. Endocr. 33,241 (1965).CrossRefGoogle Scholar
  482. [482]
    Watts, G. F., and A. W. Diddle: Oral use of 19-nor-17β-ethinyl-testosterone to control fertility. Amer. J. Obstet. Gynec. 83,1132 (1962).PubMedGoogle Scholar
  483. [483]
    Watts, G. F., and A. W.Diddle, W. H. Gardner, and P. J. Williamson: Pregnancy following withdrawal from oral contraceptive measures. Amer. J. Obstet. Gynec. 90,401 (1964).PubMedGoogle Scholar
  484. [484]
    Weber, L. M.: Hormon-Präparate im Dienste ethisch vertretbarer Geburtenregelung. Arzt und Christ 2,116 (1961).Google Scholar
  485. [485]
    Wetterberg, L.: Oral contraceptives and acute intermittent porphyria. Lancet 1964 II, 1178.CrossRefGoogle Scholar
  486. [486]
    W.H.O.: Mechanism of action of sex hormones and analogous substances. Wld Hlth Org. teehn. Rep. Ser. 303,(1965).Google Scholar
  487. [487]
    W.H.O. Clinical aspects of oral gestogens. Wld Hlth Org. techn. Rep. Ser. 326,(1966).Google Scholar
  488. [488]
    Wied, G. L., and M. E. Davis: Provest and Provera: A comparative study. Int. J. Fertil. 8,601 (1963).PubMedGoogle Scholar
  489. [489]
    Wilkins, L.: Masculinization of the female fetus due to the use of certain synthetic oral progestins during pregnancy. Arch. Anat. micr. Morph, exp. 48,313 (1959).Google Scholar
  490. [490]
    Wilkins, L. Masculinization of female fetus due to use of orally given progestins. J. Amer. med. Ass. 172,1028 (1960).CrossRefGoogle Scholar
  491. [491]
    Wilkins, L. H. W.Jones, G. H. Holman, and R. S. Stempel: Masculinization of the female fetus associated with administration of oral and intramuscular progestins during gestation: Nonadrenal female pseudohermaphrodism. J. clin. Endocr. 18,559 (1958).PubMedCrossRefGoogle Scholar
  492. [492]
    Winter, I. C.: The incidence of thromboembolism in Enovid risers. Metabolism 14,422 (1965).PubMedCrossRefGoogle Scholar
  493. [493]
    Zanartu, J.: Effect of synthetic oral gestagens on cervical mnscus and sperm penetra tion. Int. J. Fertil. 9,225 (1964).PubMedGoogle Scholar
  494. [494]
    Zanartu, J., and C. Navarro : Long-acting depo progestagens associated with oral estrogens in human fertility control. Excerpta med. (Amst.), Int. Congr. Ser. 111,351 (1966).Google Scholar
  495. [495]
    Zander, J.: Die Ausscheidung des Pregnandiolkomplexes nach Injektion von Prog esteron beim Menschen. Geburtsh. u. Frauenheilk. 14,402 (1954).Google Scholar
  496. [496]
    Zander, J. Die gestagen wirksamen Hormone im Organismus. Geburtsh. u. Frauenheilk. 17,876 (1957).Google Scholar
  497. [497]
    Zander, J. Neuere Erkenntnisse über die natürlichen Gestagene im menschlichen Organismus. 6. Sympos. dtsch. Ges. Endokr. Kiel 1959,S.U. Berlin-Göttingen-Heidelberg: Springer 1960.Google Scholar
  498. [498]
    Zander, J., u. H. A. Müller: Über die Methylandrostendiolbehandlung während einer Schwan gerschaft. Geburtsh. u. Frauenheilk. 13,216 (1953).Google Scholar

Copyright information

© Springer-Verlag / Berlin · Heidelberg 1968

Authors and Affiliations

  • J. Haller

There are no affiliations available

Personalised recommendations